Clinic Medicine

• Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
• 柳叶刀发表迄今最大规模的新型冠状病毒病例临床和治疗数据
• 重大进展|打破认知，复旦大学蓝斐/樊嘉等人发现2019-nCoV损害肝功能的机制，应对患者进行肝功能异常特别护理
• Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection
• 糖皮质激素是否可以用于治疗新型冠状病毒肺炎？
• On the use of corticosteroids for 2019-nCoV pneumonia
• 全球规模最大 | 钟南山团队首次报道新冠肺炎临床特征：影像学假阴性问题严重，需多方面结合诊断疾病
• Clinical Characteristics of Coronavirus Disease 2019 in China
• 钟南山团队千人病例研究：半数患者就诊时不发热，个别潜伏期长达24天
• 感染COVID-19孕产妇的风险是什么？
• What are the risks of COVID-19 infection in pregnant women?
• 柳叶刀：初步证据表明，妊娠晚期SARS-CoV-2感染不会引起母婴间垂直传播
• Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records
• Lancet | 警惕，加拿大新型冠状肺炎患者康复出院，却还携带病毒！这是人类从未见过的！
• First imported case of 2019 novel coronavirus in Canada, presenting as mild pneumonia
• 重大新发现 | 广州医科大学何健行团队首次发现癌症患者更易感新冠肺炎，预后更差
• Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
• 新冠影响男性生育能力？肾脏睾丸易感染，科学家建议康复患者检查生殖系统
• ACE2 Expression in Kidney and Testis May Cause Kidney and Testis Damage After 2019-nCoV Infection
• 新知丨炎症风暴——让任何一个强壮的成年人濒临绝境
• 中国科大对新冠肺炎“炎症风暴”研究取得若干进展
• 亚裔更易感染新冠病毒？No，吸烟者才危险！
• 575家医院，2007例病例，这项大型研究详细分析了癌症患者感染新冠病毒的临床特征
• Pathological findings of COVID-19 associated with acute respiratory distress syndrome
• 顶级医学期刊NEJM | 全球首次报道无症状的人可以携带新型冠状病毒
• Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China
• Lancet | 李文亮：要是早一点披露疫情，现在情况会好得多
• Li Wenliang
• 感染SARS-CoV-2的癌症患者现况：基于中国的一项全国性分析
• NEJM官方翻译|德国撤侨出现无症状新冠病毒携带者
• 重大进展 | 北京大学陆荫英团队发现新冠肺炎胖子及癌症患者易感的潜在原因
• Two Things about COVID-19 Might Need Attention
• 冠状病毒的肠道感染：SARS-CoV-2是否可经粪-口途径传播？
• Enteric involvement of coronaviruses: is faecal–oral transmission of SARS-CoV-2 possible?
• 柳叶刀发布全球首份新冠肺炎病理报告，病毒主要攻击人体肺部
• Pathological findings of COVID-19 associated with acute respiratory distress syndrome
• JAMA首次发表 | 警惕，潜伏期达19天，无症状新冠肺炎病毒携带者可能成为超级传播者
• Presumed Asymptomatic Carrier Transmission of COVID-19
• 重大进展 | 实锤！首次体内表征睾丸组织ACE2的表达，SARS-CoV-2可能感染和损害男性生殖系统
• scRNA-seq Profiling of Human Testes Reveals the Presence of ACE2 Receptor, a Target for SARS-CoV-2 Infection, in Spermatogonia, Leydig and Sertoli Cells
• BMJ重磅 | 浙江大学李兰娟团队首次报道浙江省的新冠肺炎情况：症状轻，发病快
• Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series
• 0感染 | 武汉大学王行环团队发现戴N95口罩能显著降低医护人员新冠肺炎的感染
• Association between 2019-nCoV transmission and N95 respirator use
• 重大进展 | 中国多单位合作，发现新冠肺炎患者免疫系统失调，随之疾病进展，T细胞迅速减少，应对患者免疫系统进行监控
• Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019 (COVID-19)
• NEJM重磅 | 中国学者首次揭示新冠病毒在体内的改变模式：与流感类似，但不同于SARS
• SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients
• 重磅 | 王福生院士领衔，首份新冠逝者病理报告发布，意义重大及深远！
• Pathological findings of COVID-19 associated with acute respiratory distress syndrome
• 苏州市立医院最新发现：新冠病毒可攻击肾脏和睾丸，应关注年轻男性患者生育力
• ACE2 Expression in Kidney and Testis May Cause Kidney and Testis Damage After 2019-nCoV Infection
• COVID-19相关急性呼吸窘迫综合征的病理改变
• Pathological findings of COVID-19 associated with acute respiratory distress syndrome
• 中国团队NEJM论文：提示无症状或轻症新冠肺炎患者传染性
• 武大最新研究：新冠症状越来越隐蔽，有可能长期无症状潜伏
• Caution: Clinical Characteristics of COVID-19 Patients Are Changing at Admission
• 中国研究表明儿童可能和成人一样易感 | 新冠肺炎最新动态
• Coronavirus latest: children are as susceptible as adults, study suggests
• 重大发现 | 浙江大学沈晔团队首次发现泪水及结膜分泌物有新冠病毒，警惕新的传播方式
• 2019-nCoV transmission through the ocular surface must not be ignored
• Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS‐CoV‐2 infection
• JAMA重磅 | 武汉大学徐海波/李一荣首次发现康复患者仍可能是病毒携带者，可能需重新评估出院标准
• Positive RT-PCR Test Results in Patients Recovered From COVID-19
• 第一例新冠肺炎逝者遗体解剖报告：病变仍聚焦肺部，其他脏器损伤证据不足
• 新型冠状病毒肺炎死亡尸体系统解剖大体观察报告
• 首次，医院病房空气中检出新冠病毒，来自吉林大学华树成团队的最新论文
• Clinical Data on Hospital Environmental Hygiene Monitoring and Medical Staff Protection during the Coronavirus Disease 2019 Outbreak
• 顶级医学期刊NEJM | 钟南山团队新冠肺炎临床特征，与先前该团队发表的文章相比，众多数据发生变更
• Clinical Characteristics of Coronavirus Disease 2019 in China
• 重大进展 | 复旦大学等多机构合作，首次详细报道新冠病毒对肝脏的损害，同时发现洛匹那韦/利托那韦的应用可能进一步损害肝脏
• Clinical Features of COVID-19 Related Liver Damage
• NEJM钟南山团队新冠肺炎论文 | 钟南山解读+官方翻译
• 专家论坛 | 对新型冠状病毒肺炎重症患者诊治中的几点思考
• 对新型冠状病毒肺炎重症患者诊治中的几点思考
• 重大进展 | 中国多机构合作，发现常用药物潘生丁可以改善部分新冠肺炎患者预后
• Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction
• 云南农大：茶叶有效成分强力结合新冠病毒S蛋白并阻断其与ACE2受体结合 具有防治新冠病毒感染的潜力
• 简洁版 | 重症新型冠状病毒肺炎管理专家推荐意见
• 重症医护人员防护 | 重症新型冠状病毒肺炎管理专家推荐意见
• 重症型患者转运 | 重症新型冠状病毒肺炎管理专家推荐意见
• 规范与建议 | 重症新型冠状病毒肺炎管理专家推荐意见
• 重症新型冠状病毒肺炎管理专家推荐意见
• 李兰娟院士团队在The BMJ发表文章：浙江省2019新型冠状病毒感染患者的临床特征：一项回顾性病例系列研究
• 诊治经验 | 新型冠状病毒肺炎患者继发细菌感染防治的体会与建议
• 新型冠状病毒肺炎患者继发细菌感染防治的体会与建议
• 专家论坛 | 新型冠状病毒肺炎合并严重ARDS的重要手段——ECMO治疗
• 新型冠状病毒肺炎合并严重ARDS的重要手段——ECMO治疗
• 专家建议 | 重症新型冠状病毒肺炎患者支气管镜操作流程推荐意见
• 重症新型冠状病毒肺炎患者支气管镜操作流程推荐意见
• 规范与建议 | 高原地区重型、危重型新型冠状病毒肺炎诊治专家建议（试行第一版）
• 高原地区重型、危重型新型冠状病毒肺炎诊治专家建议（试行第一版）
• JAMA重磅 | 首次在血液及粪便中发现新冠病毒，洛匹那韦/利托那韦使用可能出现众多副作用
• Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore
• COVID-19相关的肝损伤：诊治与挑战
• Liver injury in COVID-19: management and challenges
• 中国专家共识：新冠病毒疫情期间妇科诊疗防控
• 首次证实：新冠病毒攻击中枢神经系统！
• 专家论坛 | 疫情中的重症医学
• 疫情中的重症医学
• 柳叶刀作者专访 | COVID-19死亡病人的危险因素有哪些？
• Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
• 重大进展 | 刘磊/刘军/蒋澄宇首次发现新冠肺炎患者体内细胞因子变化图谱及预后的规律
• Elevated levels of plasma cytokines in COVID-19 reflect viral load and lung injury
• 实锤！第三军医大学陈永文/吴玉章首次发现新冠病毒对肾脏损害的直接证据，警惕尿液新传播方式
• Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
• Lancet最新 | 北京大学姜保国团队首次提出对新冠肺炎患者进行分类治疗
• Comorbidities and multi-organ injuries in the treatment of COVID-19
• 曹彬等学者《柳叶刀》发文 揭示新冠致死危险因素
• 世卫：疫情全球大流行迫近，柳叶刀：中国学者首次揭新冠死亡危险因素
• 《柳叶刀》最新研究：首次描述COVID-19患者病情进展全过程
• 专家论坛 | 关注新型冠状病毒肺炎重症患者 ICU 后综合征： 防治并重
• JAMA重磅 | 首次，谭文杰团队同时在血液，粪便等组织检测到新冠病毒，谨防呼吸道以外传播途径
• Detection of SARS-CoV-2 in Different Types of Clinical Specimens
• 专辑 | 抗击新冠肺炎(COVID-19)疫情重症医学专辑（截至3月11日）
• 重症护理 | 援鄂重症专科护士在新型冠状病毒感染肺炎 救治工作中的作用
• 援鄂重症专科护士在新型冠状病毒感染肺炎救治工作中的作用
• NEJM重大进展 | 中国学者首次报道儿童感染新冠肺炎的情况：需鉴别诊断，引起中度至重度呼吸系统疾病
• Detection of Covid-19 in Children in Early January 2020 in Wuhan, China
• Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China
• COVID-19对消化系统疾病诊治的影响
• Implications of COVID-19 for patients with pre-existing digestive diseases
• 父母最关心的数据——儿童新冠肺炎病情和治疗|中国团队重磅研究
• 突破 | 中国科学技术大学魏海明团队发现新冠肺炎高致死率的潜在原因：正常免疫细胞成为“带毒”的免疫细胞，托珠单抗可改善症状
• Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients
• Nature Medicine | 出院又复阳？龚世堂/张康/唐金陵/夏慧敏揭示儿童新冠肺炎的临床特征，直肠拭子测试有参考意义
• Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding
• 评估十位儿童的新冠病毒感染特征 |《自然-医学》
• Lancet强势推出 | 新冠肺炎高死亡率很大原因是细胞因子风暴引起
• COVID-19: consider cytokine storm syndromes and immunosuppression
• Nature Medicine | 打破谣言，新冠肺炎患者能产生抗新冠病毒的抗体
• Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19
• NEJM官方翻译|中国团队洛匹那韦-利托那韦治疗重症COVID-19
• A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
• 李文辉： 新冠病毒大分子药物研发面临两大挑战
• NEJM重大进展 | 中国学者强力合作，连发2篇，首次报道儿童感染新冠肺炎的情况：需鉴别诊断，临床症状较温和
• SARS-CoV-2 Infection in Children
• NEJM重磅 | 随机对照研究，王辰院士等揭示洛匹那韦–利托那韦治疗重症新冠肺炎无效
• 《柳叶刀-胃肠病学和肝脏病学》：预防失代偿期肝硬化患者感染SARS-CoV-2
• Prevention of SARS-CoV-2 infection in patients with decompensated cirrhosis
• 克力芝临床试验结果出炉：疗效不显著、副作用更常见
• 洛匹那韦/利托那韦治疗重症新型冠状病毒肺炎研究后记
• NEJM官方翻译|新冠肺炎武汉患儿大多病情轻，约16%无症状
• NEJM评论新冠肺炎首项临床试验：寻找有效疗法|附约稿声明
• Covid-19 — The Search for Effective Therapy
• JAMA首发 | 致死率高达67%，美国首次批露重症患者的临床表现，特征和结局
• Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State
• 美国开展新冠疫苗临床试验，科学家最关心哪些问题？
• Science | 世界卫生组织推出4种药物组合试验：包括瑞德昔韦及羟氯喹
• WHO launches global megatrial of the four most promising coronavirus treatments
• 这些新冠肺炎疗法靠谱吗？NEJM主编讨论了
• Nat Commun：干细胞因子和外泌体吸入疗法有望治疗肺纤维化和肺部炎症
• Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis
• 重磅 | 陈志南院士发现美普珠单抗可有效及安全治疗新冠肺炎患者
• Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial
• Lancet子刊 | 首次，华中科技大学揭示新冠肺炎孕妇的临床特征以及新生儿结局
• Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study
• Management of pregnant women infected with COVID-19
• 这种你我都打过的疫苗，也许能预防新冠感染：4国即将启动卡介苗临床试验
• 新冠损伤男性生殖功能出现首个临床证据
• Effect of SARS-CoV-2 infection upon male gonadal function: A single center-based study
• 选择合适的营养保健品可以帮助预防控制流感和冠状病毒？
• “一蹴而就 还是欲速不达” 新冠病毒疫苗现状报告
• SARS-CoV-2 vaccines: status report
• V路演 | 高基民：CAR-T之后，抗癌新利器CAR-NK细胞疗法防治COVID-19初见成效！
• JAMA发布3项新研究：胎儿是否在子宫内就已感染新冠病毒？
• Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother to Her Newborn
• Antibodies in Infants Born to Mothers With COVID-19 Pneumonia
• Neonatal Early-Onset Infection With SARS-CoV-2 in 33 Neonates Born to Mothers With COVID-19 in Wuhan, China
• JAMA重磅 | 武汉大学连续发表2项重要研究成果，揭示新冠病毒可能会通过母婴垂直传播
• Can SARS-CoV-2 Infection Be Acquired In Utero?More Definitive Evidence Is Needed
• 首个临床证据：武大中南医院发现，新冠病毒损害男性性腺，提示了潜在的性腺功能减退
• BMJ | 首次，华中科技大学宁琴团队系统描述患有新冠肺炎的死者的临床特征：男性老年人偏多，易引发多器官功能障碍
• Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study
• 性腺功能会受影响，最新论文为新冠攻击睾丸功能提供间接临床证据
• JAMA | 新发现，刘映霞/张政/刘磊发现输注恢复期患者血浆，可改善COVID-19重症患者临床症状，但仍需进一步试验
• Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
• 重大进展 | 王红阳/陈薇/肖传乐率先解析新冠肺炎患者康复期 血液免疫学特征
• Immune Cell Profiling of COVID-19 Patients in the Recovery Stage by Single-Cell Sequencing
• 研究发现：115例新冠患儿中53%无症状
• 儿童新型冠状病毒感染专栏
• Clinical Characteristics of Covid-19 in China
• NEJM新冠病毒大型Q/A，钟南山在线答疑各国专家
• 新冠母婴传播有新证据？
• Can SARS-CoV-2 Infection Be Acquired In Utero?More Definitive Evidence Is Needed
• 应用SIRS与qSOFA两种模型的评价结果真的准确吗？
• A Comparison of the Quick-SOFA and Systemic Inflammatory Response Syndrome Criteria for the Diagnosis of Sepsis and Prediction of Mortality: A Systematic Review and Meta-Analysis
• 重大进展 | 随机对照结果出炉，武汉大学张旃团队发现羟氯喹可显著改善新冠肺炎患者临床症状，更大规模的临床试验仍需要
• Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial
• 首次 | 张政/刘磊报道新冠肺炎复阳患者的临床症状：症状及年龄更轻，没有证据表明有传染性
• Clinical characteristics of the recovered COVID-19 patients with re-detectable positive RNA test
• 突破 | 曹诚/毛青等首次发现新冠肺炎患者肺损伤的机制，同时找到了潜在的治疗方法
• Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation
• 再显奇效 | 瑞德昔韦再次成功治愈重症新冠肺炎患者，有望临床推广使用
• A Community Transmitted Case of Severe Acute Respiratory Distress Syndrome due to SARS CoV2 in the United States
• BMJ Best Practice 再度更新：COVID-19疾病专题
• 研究9位患者的SARS-CoV-2病毒排出｜《自然》论文
• Virological assessment of hospitalized patients with COVID-2019
• JAMA重磅 | 美国首次报道轻度流感样新冠肺炎患者临床数据：病情较轻，比例较高
• Community Prevalence of SARS-CoV-2 Among Patients With Influenzalike Illnesses Presenting to a Los Angeles Medical Center in March 2020
• Ensuring global access to COVID-19 vaccines
• 治疗COVID-19的线索：间充质干细胞治疗H7N9感染引起ARDS的临床研究
• Clinical Study of Mesenchymal Stem Cell Treatment for Acute Respiratory Distress Syndrome Induced by Epidemic Influenza A (H7N9) Infection: A Hint for COVID-19 Treatment
• 王辰院士团队分享方舱医院经验，《柳叶刀》发表
• Fangcang shelter hospitals: a novel concept for responding to public health emergencies
• 钟南山院士团队初步阐明连花清瘟抗新冠肺炎病毒的机制
• Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) in vitro
• Respiratory virus shedding in exhaled breath and efficacy of face masks
• 外科口罩或能阻止有症状人群的季节性冠状病毒传播｜《自然-医学》
• Nature Medicine | 最新，外科口罩可以防止有症状的人传播人类冠状病毒和流感病毒
• 重大发现 | 南京医科大学刘云等团队发现新冠病毒可能不会感染男性生殖系统
• Detection of 2019 novel coronavirus in semen and testicular biopsy specimen of COVID-19 patients
• 重磅 | BMJ Best Practice 更新提示：嗅觉 / 味觉丧失为 COVID-19 关键症状
• 望月新一“ABC猜想”的“天书论文”即将发表；FDA紧急授权氯喹和羟基氯喹治疗COVID-19 等| 本周值得读·科研生涯
• 新增入院人数继续下降, 累计死亡1766例！鹿特丹、马城方舱医院，你觉得两处够用吗？
• 被新冠肺炎攻陷的欧洲为什么不抄中国的“答案”？
• 呼啦圈防身，卫生纸上锁…为了防疫，歪果仁真是脑洞大开了！
• 荷兰新冠时间线（三）——终于可以停课宅家了
• 荷兰新增病例再次破千｜黄山“爆了”，德国、西班牙正在好转，美国停止向加拿大出口N95，加拿大表示受伤了
• 湖北“抗疫满分”县长直播带货，数百万人围观
• 1岁女婴确定为无症状感染者，父亲此前已确诊
• 新冠肺炎康复者血液，美国医院的救命稻草？
• How blood from coronavirus survivors might save lives
• 防治新冠肺炎，中医药如何发挥作用?
• 重大进展 | 闻玉梅/姜世勃等发现新冠肺炎特异性抗体可长期存在，老年人的含量明显高于年轻人
• Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications
• JAMA长文 | 情况不容乐观，首次报道意大利ICU新冠肺炎患者的临床状况及预后：死亡率高达26%
• Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy
• 首个新冠撤稿论文，深圳三院法匹拉韦治疗新冠临床试验论文被杂志临时移除
• Target-Specific and Selective Drug Design for COVID-19 Using Deep Generative Models
• Understanding pathways to death in patients with COVID-19
• 张改平： 力争把特定疫苗做到最高境界
• 美《国家科学院学报》刊文：康复者血浆疗法安全有效
• Effectiveness of convalescent plasma therapy in severe COVID-19 patients
• Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
• 新冠肺炎流行期间，儿童防护要点有哪些？
• NEJM发表北京协和医院新冠肺炎研究：合并凝血异常和抗磷脂抗体
• Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19
• “盘一盘”新冠肺炎药物临床试验
• 新冠病毒在雪貂体内感染模型建立和反向遗传系统研究
• Infection and Rapid Transmission of SARS-CoV-2 in Ferrets
• An infectious cDNA clone of SARS-CoV-2
• 中国疫情有效控制，患者越来越少，入组不够的临床试验怎么办
• Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks
• 瑞德西韦同情用药结果显示“有希望”！专家：需更多临床试验支持
• 瑞德西韦首个临床用药结果公布！“人民的希望”尚未成真
• 瑞德西韦用药结果在NEJM发布：重症死亡率13%，近半数重症患者已出院
• NEJM重磅 | 大型临床试验出炉，瑞德昔韦可治疗新冠肺炎重症患者：68%患者观察到临床症状改善
• Compassionate Use of Remdesivir for Patients with Severe Covid-19
• 首份瑞德西韦治疗新冠临床研究，“结果令人鼓舞”
• NEJM翻译+述评|瑞德西韦同情治疗重症新冠肺炎，68%临床获益，评价疗效尚早
• 新冠病毒为何如此诡异
• 新发现 | 北京大学来鲁华等团队发现黄芩提取物可抗新冠病毒，有望作为治疗药物
• Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro
• 如果人们买不起，那新冠救命药有什么用？｜《科学》新闻
• Would-be coronavirus drugs are cheap to make
• 好消息！中国又有2款新冠疫苗将进入临床试验
• 美国专业学会联合声明：COVID-19患者应继续服用ACE抑制剂和ARB
• Patients with COVID-19 Should Continue ACE Inhibitors and ARBs: A Joint Statement from U.S. Heart Groups
• 新发现 | 中国多个团队同时发现黄芩提取物可抗新冠病毒，有望作为治疗药物
• Discovery of baicalin and baicalein as novel, natural product inhibitors of SARS-CoV-2 3CL protease in vitro
• The BMJ：目前 COVID-19 的应对方案可能存在问题且证据薄弱
• Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal
• 如果新冠疫苗真的上市了，人手一支可能吗？
• If a coronavirus vaccine arrives, can the world make enough?
• NEJM：纽约近期孕妇新冠病毒阳性率15%，其中88%无症状
• Universal Screening for SARS-CoV-2 in Women Admitted for Delivery
• NEJM首次 | 致敬，中国学者揭示在新冠肺炎期间23位医护人员死亡
• Death from Covid-19 of 23 Health Care Workers in China
• 母乳喂养影响婴儿肠道内的病毒定植 |《自然》论文
• The stepwise assembly of the neonatal virome is modulated by breastfeeding
• 新冠疫苗全球研发现状：78个已确认，5个进入临床
• The COVID-19 vaccine development landscape
• 高血糖或可解释为什么某些流感、新冠患者会出现严重症状｜Science Advances
• O-GlcNAc transferase promotes influenza A virus–induced cytokine storm by targeting interferon regulatory factor–5
• JAMA子刊 | 华中科技大学胡波等团队系统报道新冠肺炎患者的神经学临床表现
• Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China
• COVID-19如何致人死亡？新冠肺炎的治疗难题
• How does COVID-19 kill? Uncertainty is hampering doctors’ ability to choose treatments
• 对新冠并发症的抗生素治疗可导致耐药性细菌的激增｜《科学》新闻
• Antibiotic treatment for COVID-19 complications could fuel resistant bacteria
• 瑞德西韦美国临床数据泄露：大部分重症患者不到一周即可出院
• SARS-CoV-2 病毒性脓毒症：临床发现和科学假说
• SARS-CoV-2 and viral sepsis: observations and hypotheses
• 北医三院团队NEJM论文：武汉孕产妇新冠肺炎重症率较低
• Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan, China
• NEJM最新 | 规模最大，乔杰/赵扬玉揭示新冠肺炎孕妇患者的临床症状及预后：症状更轻，不会发生母婴垂直传播
• 最新 | 武汉大学李红良团队解决高血压合并新冠肺炎患者临床用药问题
• Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19
• Cell突破 | 首次阐述清楚合并症患者中更经常观察到严重的COVID-19病例的机制
• Imbalanced host response to SARS-CoV-2 drives development of COVID-19
• Lancet | 曹彬团队首次提出SARS-CoV-2产生病毒性败血症的假说，为临床及基础研究指明方向
• Science重磅 | 瑞德昔韦治疗新冠肺炎效果显著，猴子可以作为新冠肺炎的动物模型
• Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model
• 全球疫苗免疫联盟CEO：新冠疫苗难在哪儿？
• 失而复得 | “中国首篇新冠被撤论文”重新上线，涉及法匹拉韦临床试验，结论及讨论更加委婉
• Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
• Lancet子刊 | 广州医科大学钟南山/李时悦等首次描述新冠肺炎患者的静脉栓塞的临床表现及管理
• Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19
• 浙大王福俤/闵军霞团队等发布全球最大新冠肺炎重症及死亡风险荟萃分析
• Comorbid Chronic Diseases and Acute Organ Injuries Are Strongly Correlated with Disease Severity and Mortality among COVID-19 Patients: A Systemic Review and Meta-Analysis
• 重大进展 | 中国多个团队同时发现新冠病毒能在产生特异性抗体的患者体内长期存在
• Long-term Co-existence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) with Antibody Response in Non-severe Coronavirus Disease 2019 (COVID-19) Patients
• Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications
• 武汉COVID-19患者的心脏损伤
• Cardiac Injury with COVID-19 in Wuhan
• BMJ首次 | 尿液中检测到新冠病毒，浙江大学梁廷波团队发现粪便排毒时间最长
• Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort stud
• Barabási组最新：网络科学大幅缩小新冠特效药搜索范围至81种
• Network Medicine Framework for Identifying Drug Repurposing Opportunities for COVID-19
• 最新 | 李红良团队系统介绍COVID-19的特点及其对心血管系统的影响
• The Science underlying COVID-19: Implications for the CardiovascularSystem
• 实锤！美国证实羟氯喹不仅对新冠无效，还会增加死亡率！
• Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19
• 在COVID-19治疗中应重视静脉血栓栓塞症的预防
• Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19
• 钟南山团队：咽漱液用于新冠病毒核酸检测准确率高于鼻拭子
• Effect of throat washings on detection of 2019 novel coronavirus
• 钟南山院士团队在《欧洲呼吸杂志》发表全国1590例新冠病毒感染患者基础合并症与临床预后的研究结果
• Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis
• 瞿介明教授、徐金富教授团队在《欧洲呼吸杂志》发表文章：COVID-19 年龄与临床特征、预后之间的关联
• Association Between Ages and Clinical Characteristics and Outcomes of Coronavirus Disease 2019
• Lancet子刊 | 重大发现，华中科技大学团队发现新冠肺炎病毒抗体可长期存在，羊水中不能检测到新冠病毒
• No SARS-CoV-2 detected in amniotic fluid in mid-pregnancy
• JAMA重磅 | 美国最大规模的新冠肺炎病例研究：有创机械通气死亡率达到88.1%
• Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area
• Neurosurgery in an infant with COVID-19
• No SARS-CoV-2 detected in amniotic fluid in mid-pregnancy
• Practical recommendations for the management of diabetes in patients with COVID-19
• 新研究：瑞德西韦小鼠实验中有生殖毒性，严重影响精子质量
• A preliminary study on the reproductive toxicity of GS-5734 on male mice
• 新发现 | 新冠病毒更偏爱男性的潜在原因被揭示：肺表达更多及更高的ACE2
• Expression of ACE2, the SARS-CoV-2 receptor, and TMPRSS2 in prostate epithelial cells
• 后遗症暴露？瑞德西韦小鼠实验被证有生殖毒性，严重影响精子质量
• 抵御炎症风暴，你用对武器了吗？
• Nature Medicine | 最新发现，鼻子或是新冠病毒感染的“毒库”
• SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes
• ​WHO推荐的四种最有希望的新冠特效药相继“陨落”，政客的鼓吹让新冠治疗陷入困境
• Chloroquine hype is derailing the search for coronavirus treatments
• The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin
• Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
• Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
• 使用羟氯喹和阿奇霉素治疗的新冠肺炎患者出现心脏病变 |《自然-医学》论文
• 北京科兴公司研发的新冠疫苗在猴子试验中有效，已启动一期人体临床试验｜《科学》新闻
• 专家论坛丨重症医学质量控制是重症新型冠状病毒肺炎救治的着力点
• 重症医学质量控制是重症新型冠状病毒肺炎救治的着力点
• 共识与建议丨新型冠状病毒肺炎患者镇痛镇静策略的专家建议
• 新型冠状病毒肺炎患者镇痛镇静策略的专家建议
• 专家论坛丨围绕重症医学质控中心职能优势，提升重型新型冠状病毒肺炎患者救治效率
• 围绕重症医学质控中心职能优势，提升重型新型冠状病毒肺炎患者救治效率
• 专家论坛丨新型冠状病毒肺炎从普通型到重症型如何早期识别和应对——浅谈在金银潭医院的救治体会
• 新型冠状病毒肺炎从普通型到重症型如何早期识别和应对——浅谈在金银潭医院的救治体会
• 方舱庇护医院：应对公共卫生紧急状况的新理念
• 西湖大学郑钜圣等发现：肠道菌群可能是健康人群易感新冠肺炎并发展为重症的重要因素
• Gut microbiota may underlie the predisposition of healthy individuals to COVID-19
• 冠状病毒警报：英国专家调查儿童罕见综合症是否与新冠病毒有关
• Coronavirus alert: Rare syndrome seen in UK children
• 重大进展 | 周溪/尚游/张定宇/邱洋/林树海首次揭示新冠患者血浆代谢组学及脂质组学的变化
• Plasma Metabolomic and Lipidomic Alterations Associated with COVID-19
• 新冠肺炎困境：儿童轻症为主的原因试解
• Will children reveal their secret? The coronavirus dilemma
• 死亡的中度至危重COVID-19患者的临床特征
• Clinical Features of Moderately to Critically Ill Patients with COVID-19 Who Die
• 恢复期血浆在治疗COVID-19方面有潜在效用
• Convalescent Plasma Has Potential Utility for Managing COVID-19
• 3项瑞德西韦临床试验结果同天公布：一项显示康复时间缩短31%
• 未见明显疗效！《柳叶刀》发表瑞德西韦中国临床研究
• Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
• Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19
• 瑞德西韦首项临床随机对照试验：并未带来显著临床获益，需更多研究
• NEJM病例：纽约一家医院肾移植Covid-19患者死亡率高达28%
• Covid-19 and Kidney Transplantation
• NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19
• 全球性随机双盲住院新冠肺炎患者试验：瑞德西韦显著缩短患者康复所需时间
• As the coronavirus spreads, a drug that once raised the world’s hopes is given a second shot
• 中美瑞德西韦试验结果，截然相反
• Towards precision management of cardiovascular patients with COVID-19 to reduce mortality
• Nature Medicine | 100%阳性，重庆医科大学胡接力/陈娟/黄爱龙深入揭示COVID-19患者抗体应答特征
• Antibody responses to SARS-CoV-2 in patients with COVID-19
• 寻找COVID-19的有效疗法：把握度不足的研究所面临的挑战
• Remdesivir for COVID-19: challenges of underpowered studies
• COVID-19的药物再利用潜力 |《自然》论文
• A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
• Science | 再添实锤！新冠病毒可有效感染小肠上皮细胞
• SARS-CoV-2 productively infects human gut enterocytes
• PNAS | 重大进展，中国科学技术大学徐晓玲/魏海明团队发现托珠单抗能有效治疗新冠肺炎重症患者
• Effective Treatment of Severe COVID-19 Patients with Tocilizumab
• Science突破 | 徐华强/张岩/张抒扬/许叶春合作团队解析新冠重要药靶RNA复制酶结合瑞德西韦的结构并揭示其抑制机制
• Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
• 最新 | 张文宏系统介绍新冠重症患者的处理和治疗的上海经验
• COVID-19: treating and managing severe cases
• 新冠肺炎男性死亡率是女性2倍，美国医生已开始尝试为男性患者注射性激素
• COVID-19 study shows that men have over double the death rate of women
• COVID-19 kills more men than women. The immune system may be why
• Can Estrogen and Other Sex Hormones Help Men Survive Covid-19?
• 2分钟视频讲清楚3篇《新英格兰医学杂志》Covid-19临床特征重磅论文
• 新冠病毒侵入人体全过程！从脚趾到大脑，科学家追踪到病毒对身体的巨大摧残
• How does coronavirus kill? Clinicians trace a ferocious rampage through the body, from brain to toes
• 新冠病毒感染人体最新鉴定出332种蛋白质相互作用
• 为什么说有抗体不等于能免疫？
• What Immunity to COVID-19 Really Means
• 科学家发现新冠肺炎2型糖尿病患者血糖控制范围
• Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes
• Cell Metabolism | 全球首次，李红良/黄晓东/张丙宏/郭姣揭示2型糖尿病患者血糖控制与新冠肺炎患者结局的关系
• Immunity | 董晨/陈方/秦成峰发现新冠肺炎康复患者能产生针对新冠病毒的特异性抗体
• Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals
• 728对双胞胎研究发现：发热嗅觉丧失等新冠症状受遗传影响
• Self-reported symptoms of covid-19 including symptoms most predictive of SARS-CoV- 2 infection, are heritable
• 预防肺结核的卡介苗可减轻新冠影响？柳叶刀：请遵循世卫建议
• Considering BCG vaccination to reduce the impact of COVID-19
• Hepatology | 李红良团队首次提出天冬氨酸转氨酶异常与新冠肺炎死亡风险相关
• Longitudinal association between markers of liver injury and mortality in COVID‐19 in China
• 症状出现前的SARS-CoV-2传播
• Presymptomatic Transmission of SARS-CoV-2
• Presymptomatic Transmission of SARS-CoV-2 — Singapore, January 23–March 16, 2020
• 法匹拉韦对COVID-19是否有效
• Favipiravir: A Potential Antiviral for COVID-19?
• Discovering drugs to treat coronavirus disease 2019 (COVID-19)
• 王辰、曹彬等在NEJM发文，回应读者关于洛匹那韦-利托那韦治疗Covid-19来信
• A Trial of Lopinavir–Ritonavir in Covid-19
• 训练式免疫：一种可降低SARS-CoV-2易感性和严重性的工具
• Trained immunity: a tool for reducing susceptibility and severity of SARS-CoV2 infection
• 【在线速递】COVID-19流行期间，远程医疗的作用-山东省经验
• The role of telemedicine during the COVID-19 epidemic in China—experience from Shandong province
• 北京协和医院张抒扬教授团队发文：新冠病毒对心血管系统的影响及治疗方案
• Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy
• 雄激素“助纣为虐”？最新研究发现：雄激素剥夺疗法或是男性新冠患者“救星”
• Androgen-deprivation treatments for prostate cancer could protect men from COVID-19
• Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532)
• 柳叶刀-数字医疗 | COVID-19的临床试验亟需实时整合
• A real-time dashboard of clinical trials for COVID-19
• 洛匹那韦/利托那韦和阿比朵尔对新冠肺炎轻中症的成年患者无效丨Cell Press对话科学家
• Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial
• 新冠肺炎的特效药究竟是什么？论随机对照组试验的必要性
• What is the best drug to treat COVID-19? The need for randomized controlled trials
• NEJM重大发现 | 跌出神坛！大规模队列研究，发现羟氯喹治疗新冠患者无效
• Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
• 国内展身手、非洲受欢迎、欧美遭质疑，Nature、Science齐发文：中药治疗新冠需谨慎！
• China is promoting coronavirus treatments based on unproven traditional medicines
• Unproven herbal remedy against COVID-19 could fuel drug-resistant malaria, scientists warn
• 7张图带你看懂90多种新冠疫苗的研发现状
• The race for coronavirus vaccines: a graphical guide
• 氯喹跌落神坛|NEJM大样本研究未发现羟氯喹降低Covid-19死亡或插管率
• COVID-19-Related Stroke
• 2分钟看懂NEJM：洛匹那韦/利托那韦对COVID-19的疗效
• 免疫学 | 治疗新冠肺炎的线索：细胞因子风暴和 T 细胞计数
• Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)
• Lancet | 证明有效！袁国勇团队发现联合用药治疗轻中新冠肺炎显奇效
• Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
• How Corona Virus attacks Humans and difference between different nationalities
• 重大进展 | 王红阳/陈薇/肖传乐率先解析新冠肺炎患者康复期血液免疫学特征
• Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing
• Lancet Voice 特别版 | 关于恢复期血浆治疗COVID-19的讨论
• 改善新冠肺炎合并糖尿病患者预后，控制血糖是关键 | Cell Press 对话科学家
• Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes
• 武汉协和医院杨东亮：从免疫系统寻找对抗新冠的钥匙
• 中国患者精液中检出新冠病毒，生殖系统长期影响仍未知
• Clinical Characteristics and Results of Semen Tests Among Men With Coronavirus Disease 2019
• 新冠病毒入侵之门ACE2，在男性血液中的浓度更高，或可解释男性更易感染和死亡的原因
• Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors
• 人民的“神药”跌落神坛 | 多项大规模队列研究同时表明，羟氯喹治疗新冠患者无效
• Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
• 加强医护人员筛查，预防COVID-19医院感染
• COVID-19: the case for health-care worker screening to prevent hospital transmission
• COVID-19患者胰腺损伤的血清学证据
• Serologic Evidence of Pancreatic Injury in COVID-19
• 儿科 | 消化道症状可能是新冠肺炎儿童患者的首发症状
• Clinical Characteristics of 5 COVID-19 Cases With Non-respiratory Symptoms as the First Manifestation in Children
• 分析新冠肺炎患者的呼吸系统免疫反应 |《自然-医学》论文
• Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19
• 最新研究 | 新三联抗病毒药物在2期随机临床试验中表现积极
• 进展 | Identified 40 new potential drugs that could treat COVID-19
• NETWORK SCIENTISTS IDENTIFY 40 NEW DRUGS TO TEST AGAINST COVID-19
• Multiorgan and Renal Tropism of SARS-CoV-2
• JAMA | 打破认知，大规模队列研究，儿童卡介苗接种对成年期COVID-19没有保护作用
• SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults
• COVID-19中的内皮细胞感染和内皮炎
• COVID-19: the case for health-care worker screening to prevent hospital transmission
• Characteristics and outcomes of patients with breast cancer diagnosed with SARS-Cov-2 infection at an academic center in New York City
• 【查证】《经济学人》：吸烟者较少感染，尼古丁是否真能抑制新冠病毒？
• Smokers seem less likely than non-smokers to fall ill with covid-19
• NEJM主编：不宜过度解读美国紧急授权瑞德西韦，应尽快公布全部数据
• 罕见“川崎病”重现美国，164名儿童感染，《柳叶刀》称与Covid-19直接相关
• What we know about the new Covid-19-linked illness in children
• Cell突破 | 在新冠肺炎患者和未感染者中发现针对新冠病毒的T细胞
• Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals
• T cells found in COVID-19 patients ‘bode well’ for long-term immunity
• Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors
• 人民的“神药”跌落神坛 | 随机对照试验，上海交通大学谢青等团队证明羟氯喹治疗新冠患者无效
• Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data
• Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial
• 核酸检测还能更快更准吗？自我检测是否可行？
• 疫苗专家：新冠病毒疫苗最早有望明年年底前上市
• 与其锦上添花，不如釜底抽薪，控制细胞因子风暴，改善新冠病毒肺炎预后
• 治疗有效？ 广州医科大学赖天文等人连发4篇NEJM，强烈质疑瑞德昔韦可以降低重症患者死亡率：统计使用方法，计算等有误
• Compassionate Use of Remdesivir in Covid-19
• 半年来，尸检一直在揭示新冠肺炎真容
• 罕见！新英格兰连发4篇文章质疑“人民的希望”实验结果
• 重大突破：首个新冠肺炎强效新药有望！北大谢晓亮团队Cell发布最新重磅成果，即将进入临床
• Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells
• Cell重磅 | 谢晓亮/秦川/秦成峰/金荣华从8000多种抗体中筛选出新冠病毒中和抗体，有望迅速应用于临床
• The immune system of children: the key to understanding SARS-CoV-2 susceptibility?
• SARS治愈者的抗体可以抑制SARS-CoV-2 |《自然-免疫》论文
• Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
• 小型观察性研究：关节炎治疗药物阿那白滞素对COVID-19患者有临床获益
• 英国医学杂志 (The BMJ) 刊文：方舱医院感染预防与控制的“中国经验”
• China experience: infection prevention and control in the FangCang hospitals of Wuhan
• 研制新冠肺炎强效药！北大谢晓亮团队与合作者借助高通量单细胞技术，成功筛选出多个新冠病毒高活性中和抗体
• 迫切需要COVID-19新冠肺炎恢复患者的管理计划
• Urgent need of a management plan for survivors of COVID-19
• 新冠康复者体内产生多种特异性抗体
• Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals
• 重大发现 | 吸烟居然更容易受到新冠病毒的感染，而且症症更严重
• Cigarette smoke exposure and inflammatory signaling increase the expression of the SARS-CoV-2 receptor ACE2 in the respiratory tract
• 中国上海一家医疗中心COVID-19患者的肝脏表现
• Liver Manifestations of COVID-19 Infection
• 洗手液成分对SARS-CoV-2的抗病毒效果
• Effectiveness of Hand Sanitizer Constituents Against SARS-CoV-2
• 疫情过后广州一家医院消化内科日常服务恢复情况
• Resumption of daily services in a gastroenterology department in Guangzhou, China, in the wake of COVID-19
• Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period
• 新冠病毒免疫组学研究全览丨CellPress论文速递
• Immunology of COVID-19: current state of the science
• 张伯礼：加快新冠病毒疫苗III期临床试验
• 疫苗专家：新冠病毒疫苗最早有望明年年底前上市
• 改善新冠合并糖尿病患者预后 控制血糖是关键
• 新冠肺炎为何会出现细胞因子风暴？免疫反应过度或是“元凶”
• Mathematical modeling of interaction between innate and adaptive immune responses in COVID‐19 and implications for viral pathogenesis
• “马达加斯加疗法”治新冠？世卫组织：尚无证据
• “免疫护照”不靠谱的十个原因 |《自然》评论
• Ten reasons why immunity passports are a bad idea
• 柳叶刀-糖尿病与内分泌学 | COVID-19与广受关注的基础代谢性疾病
• COVID-19: underlying metabolic health in the spotlight
• JAMA重磅 | 重大发现，儿童新冠感染率低的潜在原因被揭示：ACE2表达含量低
• Nasal Gene Expression of Angiotensin-Converting Enzyme 2 in Children and Adults
• 100%有效！“良心药”羟氯喹治疗新冠肺炎有效，遭撤稿，通讯作者表示：得修改结论
• Hydroxychloroquine plus azithromycin: a potential interest in reducing in-hospital morbidity due to COVID-19 pneumonia (HI-ZY-COVID)?
• The BMJ 发布 COVID-19 远程诊疗快速指南图表信息(Infographics)
• Covid-19: a remote assessment in primary care
• 柳叶刀发布陈薇团队新冠疫苗试验结果
• Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
• 全球首个安全有效新冠疫苗：陈薇院士团队研制，登上《柳叶刀》
• 安全有效，全球首个新冠疫苗人体数据来自中国！陈薇团队成果，《柳叶刀》重磅发布
• 新冠病毒疫苗临床试验有了初步结果，但效果仍不明确
• Coronavirus vaccine trials have their first results — but their promise is still unclear
• 中国团队发表全球首篇新冠疫苗临床论文：受试者均产生免疫应答，免疫反应减弱值得关注
• 《柳叶刀》重磅发布陈薇团队全球首个新冠疫苗人体数据，安全有效！
• Lancet | 安全！陈薇院士团队发布全球首个新冠疫苗人体试验数据！全部产生免疫应答，2期临床试验已完成注射
• 继续领跑世界！陈薇团队发布全球首个新冠疫苗人体试验数据：安全，成功诱导免疫！
• 《柳叶刀》发表首个新冠病毒疫苗人体试验，安全并能诱导快速免疫应答
• 《柳叶刀》发布中国团队新冠疫苗临床结果：安全，可快速诱导免疫应答
• Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
• 柳叶刀发布陈薇院士团队新冠疫苗I期临床结果：108人全部产生免疫反应，真•人民的希望！
• 全球首个！陈薇院士新冠疫苗临床试验结果发布：全部产生免疫应答！
• NEJM重磅：美国首项瑞德西韦临床试验初步结果正式发表，作者解释备受争议的临床终点修改问题
• Remdesivir for the Treatment of Covid-19 — Preliminary Report
• 《柳叶刀》重磅发布！全球首个新冠疫苗在中国诞生，但其实真没你想象的那么乐观......
• NEJM | 随机对照临床试验刚刚出炉，神药瑞德昔韦效果有效：可降低新冠肺炎患者死亡率及缩短恢复时间
• 国际合作为新冠疫苗研发生产提供“加速度”
• Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study
• Risk assessment and prediction of severe or critical illness of COVID-19 in the elderly
• Lancet Voice 特别版 | COVID-19与类川崎病？
• An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study
• Kawasaki-like disease: emerging complication during the COVID-19 pandemic
• 新英格兰医学杂志：治疗重症Covid-19的临床建议
• Severe Covid-19
• Lancet | 震惊，规模最大，近10万参与者，羟氯喹治疗新冠会明显增加死亡率及心率失常
• 李一诺：新冠疫苗后面的国际难题
• COVID-19 Disease in Children: What Dentists Should Know and Do to Prevent Viral Spread. The Italian Point of View
• 落下帷幕 | 羟氯喹从神药到一地鸡毛，羟氯喹被停止全球测试
• 盘点 | 十项新冠疫苗研发项目进入临床开发阶段，它们的最新进展意味着什么？
• 对COVID-19感染者的患者支持
• Managing the supportive care needs of those affected by COVID-19
• 雄起 | 深圳市第三人民医院张政等团队连发Cell/Nature等3项研究成果，为临床干预新冠奠定基础
• Human neutralizing antibodies elicited by SARS-CoV-2 infection
• 《新英格兰医学杂志》主编：新冠疫苗存在很多不确定性，但值得押宝
• 上海市COVID-19疑似病例的筛查机制与早期临床危险因素识别的多中心临床研究
• Assessing risk factors for SARS-CoV-2 infection in patients presenting with symptoms in Shanghai, China: a multicentre, observational cohort study
• 褪黑素或可用于辅助治疗新冠肺炎
• COVID-19: Melatonin as a potential adjuvant treatment
• 重磅 | 连发2篇NEJM ，随机对照临床试验表明瑞德昔韦效果有效及短时间治疗可能作为首选
• Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
• 瑞德西韦5或10天治疗Covid-19正式发表：重要结果，但只是第一步
• 最新研究 | 尚无证据表明氯喹和羟氯喹对COVID-19患者有益
• 医学 | 新冠肺炎的死亡病例加深我们对该疾病发展的了解
• Novel Insights Into Illness Progression and Risk Profiles for Mortality in Non-survivors of COVID-19
• The BMJ: 更多证据不支持使用羟氯喹治疗 COVID-19 患者
• Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data
• Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial
• 争鸣 | 出现极大反转！钟南山，单鸿等人发现氯喹是潜在的治疗新冠肺炎的药物：恢复快，无重大副作用
• Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19
• Lancet Voice 特别版 | COVID-19与免疫系统
• The immunology of COVID-19: is immune modulation an option for treatment?
• Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia
• 上海地区新冠肺炎患者的临床进展
• Clinical progression of patients with COVID-19 in Shanghai, China
• 钟南山院士团队：什么样的患者容易死于新冠肺炎？
• Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China
• ISARIC报告：新冠住院患者病死率达27%
• 世界无烟日 | 吸烟与COVID-19感染
• Tobacco smoking and COVID-19 infection
• 世界无烟日丨戒烟可以减少SARS-CoV-2感染风险
• Cigarette Smoke Exposure and Inflammatory Signaling Increase the Expression of the SARS-CoV-2 Receptor ACE2 in the Respiratory Tract
• Lancet重大发现 | 羟氯喹及阿奇霉素治疗新冠伴随有癌症的患者，死亡率增加2倍以上
• Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
• COVID-19患儿的胃肠道特征：在8例患儿中的不同临床表现
• Gastrointestinal features in children with COVID-19: an observation of varied presentation in eight children
• 作者表示：原始数据不能公开！全球120位研究人员质疑羟氯喹治疗新冠会增加死亡率！
• An open letter to Mehra et al and The Lancet
• Safety fears over drug hyped to treat the coronavirus spark global confusion
• 国际著名病毒专家王林发成功研发出全球首个中和抗体检测盒，1小时快速检测！
• 单一病例提示SARS-CoV-2的垂直传播风险低
• Maternal SARS-CoV-2 Infection During the Second Trimester
• 特朗普强行带货、WHO暂停试验，盘点新冠“神药”羟氯喹的前世今生
• WHO trial suspends hydroxychloroquine treatment for new COVID-19 patients
• France bans use of hydroxychloroquine, drug touted by Trump, in coronavirus patients
• Scientists Question Validity of Major Hydroxychloroquine Study
• Hydroxychloroquine: a drug dividing the world
• JAMA争鸣 | 结果无效：随机对照试验，刘忠等发现输注恢复期患者血浆不能改善COVID-19重症/危重患者临床症状
• Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19，A Randomized Clinical Trial
• Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
• 最新研究 | SARS-CoV-2感染者术后发生肺部并发症的风险较高
• Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study
• 震惊 | 新冠数据涉嫌胡编乱造，顶级期刊Lancet及NEJM文章被撤稿，后期会撤更多的文章
• NEJM|羟氯喹未能防止Covid-19密切接触者出现症状或病情进展
• 郭天南团队：新冠重症患者血清中多种独特的分子调控 | CellPress对话科学家
• Proteomic and Metabolomic Characterization of COVID-19 Patient Sera
• 疫情以来首个科研丑闻调查！两大医学顶刊撤稿，WHO被误导
• 学术丑闻：炮制数据致多篇重磅新冠研究被撤！顶刊编辑被解雇，期刊陷入信任危机
• 重磅 | 卞修武院士领衔全球最大规模的新冠肺炎尸检报告出炉：新冠病毒可感染睾丸，肺等组织；存在多种病毒传播途径
• Autopsy of COVID-19 victims in China
• 比测体温更有效？《柳叶刀》称丧失嗅觉是新冠最强指标，优于发烧\
• Quantifying additional COVID-19 symptoms will save lives
• Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
• 柳叶刀-血液病学 | COVID-19凝血病：一个不断发展的故事
• COVID-19 coagulopathy: an evolving story
• Science及Nature连发 | 瑞德昔韦治疗新冠肺炎效果显著：早期干预效果更好
• 托珠单抗有可能减轻COVID-19患者的“细胞因子风暴”
• Tocilizumab Might Attenuate the “Cytokine Storm” in COVID-19 Patients
• 瑞德西韦减缓了新冠肺炎恒河猴的疾病进展 |《自然》论文
• BMJ重磅 | 创造奇迹！0感染，血清学检测及核酸检测都为阴性：中山大学肖海鹏团队揭示援助武汉医护人员的新冠感染情况
• Use of personal protective equipment against coronavirus disease 2019 by healthcare professionals in Wuhan, China: cross sectional study
• 港中大全球首证 新冠患者肠道微生态现失衡
• 疫情常态化防控，为何必须关注核酸检测灵敏度
• False Negative Tests for SARS-CoV-2 Infection — Challenges and Implications
• 儿童的新冠肺炎症状为什么不那么严重？答案可能和血管有关
• Why children avoid the worst coronavirus complications might lie in their arteries
• Science背靠背 | 治疗时间很重要！新冠肺炎治疗的新途径：IFN-λ成为治疗热点
• Type III interferons disrupt the lung epithelial barrier upon viral recognition
• Type I and III interferons disrupt lung epithelial repair during recovery from viral infection
• 国产新冠病毒灭活疫苗初步成果公布：安全性、有效性良好
• 重磅：1120人，两针接种阳转率100%！全球首个新冠灭活疫苗Ⅰ/Ⅱ期临床全部产生抗体
• 振奋人心 | 迎来了光明！大规模临床随机对照试验，全球首个廉价药类固醇地塞米松可以降低新冠患者30%以上的死亡率
• Coronavirus breakthrough: dexamethasone is first drug shown to save lives
• 地塞米松：首个能降低新冠肺炎重症死亡率的药物
• Coronavirus breakthrough: dexamethasone is first drug shown to save lives
• Nature重磅：首个新冠特效药？地塞米松能够减少三成重症患者死亡
• Lancet Voice 特别版 | 对细胞因子风暴的解释
• 首个降低新冠重症死亡率的药物：地塞米松“不是奇迹，但确实有用”
• 便宜货“地塞米松”刷屏！新冠首个“救命药”来了？
• 《英国医学杂志》：医务人员防护装备和使用培训对预防 COVID-19 的重要性
• Use of personal protective equipment against coronavirus disease 2019 by healthcare professionals in Wuhan, China: cross sectional study
• 世卫组织宣布停止羟氯喹治疗新冠试验
• 世卫组织：欢迎地塞米松治疗新冠试验结果但应谨慎用药
• 检测！检测！新冠病毒检测怎么做到更快、更准、更稳定？
• 新冠肺炎无症状感染者的免疫反应可能较弱 |《自然-医学》论文
• Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
• 中国团队新冠论文今日登Science封面：发现新型抗新冠病毒候选药物
• Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
• 3篇Nature Medicine | 重庆医科大学黄爱龙等团队首次揭示无症状个体的临床特征和免疫反应
• 血型与易感新冠有关？新研究：A型血风险高，O型血更安全
• 大型基因组研究：A型血新冠重症风险上升45%，O型降低35%
• Genomewide Association Study of Severe Covid-19 with Respiratory Failure
• 2分钟看懂NEJM：COVID-19与服用肾素-血管紧张素-醛固酮系统抑制剂
• Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19
• 感染COVID-19的糖尿病患者需及时进行血糖控制
• Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed
• 引领全球！中国启动新冠疫苗Ⅲ期临床试验！
• 嗅觉丧失是新冠“非典型”症状？专家回应
• 振奋人心 | 迎来了光明！武汉大学李红良等团队全球首次发现他汀类药物可以降低新冠患者40%以上的死亡率
• In-hospital Use of Statins is Associated with a Reduced Risk of Mortality among Individuals with COVID-19
• Nature关注：越来越多的线索表明，新冠病毒可引发糖尿病
• Mounting clues suggest the coronavirus might trigger diabetes
• 感染新冠病毒，还可能引发患糖尿病
• Lancet Voice | 新冠疫苗、胰岛素定价、毒蛇咬伤
• Can tocilizumab calm the cytokine storm of COVID-19?
• Tocilizumab in patients with severe COVID-19: a retrospective cohort study
• 《自然-癌症》| 癌症患者更易感COVID-19？
• 危重症新冠肺炎管理感受分享
• 吸入皮质类固醇和COVID-19：一项系统性评估与临床观点
• Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective
• 我们能否“吃”走新冠 | BMC关注世界过敏周
• Is diet partly responsible for differences in COVID-19 death rates between and within countries?
• NEJM重大新发现 | 不同人对于新冠病毒的易感性被揭示： A型血的人更易感新冠肺炎，而O型更不易感
• 他汀类药物的使用或能降低COVID-19住院患者的死亡率 | CellPress论文速递
• 药理学 | 静脉内注射维生素C可提高Covid-19治疗效果？
• Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome
• COVID-19的脂质组学和代谢组学研究揭示新冠发病机制中代谢失调 | CellPress论文速递
• Omics-Driven Systems Interrogation of Metabolic Dysregulation in COVID-19 Pathogenesis
• Development of an inactivated vaccine candidate for SARS-CoV-2
• Cell Res | 突破 ！汤楠/陈静瑜团队首次发现新冠肺炎患者肺泡可以再生
• Pulmonary alveolar regeneration in adult COVID-19 patients
• 印度要以“风速”推出新冠疫苗了！科学家：荒谬！
• Scientists scoff at Indian agency's plan to have COVID-19 vaccine ready for use next month
• 最新 | 首例报道新冠肺炎患者出现阴茎长时间异常勃起
• Priapism in a patient with coronavirus disease 2019 (COVID-19): A case report
• 专家论坛丨重型新型冠状病毒肺炎的临床决策与思考
• 重型新型冠状病毒肺炎的临床决策与思考
• An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment
• PNAS | 活久见！百年疫苗-卡介苗的接种可降低新冠肺炎死亡率
• BCG vaccine protection from severe coronavirus disease 2019 (COVID-19)
• 坏消息：免疫只是暂时的，治愈患者血液中的抗体减少
• JAMA | 一文看懂新冠所有的状况！最为全面系统盘点COVID-19的病理生理学，传播，诊断和管理
• Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19)
• Alveolar macrophage dysfunction and cytokine storm in the pathogenesis of two severe COVID-19 patients
• COVID-19=急性呼吸窘迫综合征？| Critical Care
• Critical Care and Emergency Medicine: COVID-19 research
• 分析COVID-19康复患者的循环抗体和免疫细胞反应 |《自然-医学》论文
• Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19
• 个案研究展示SARS-CoV-2经胎盘传播的证据 |《自然-通讯》论文
• Transplacental transmission of SARS-CoV-2 infection
• 首例！研究发现新生儿由母体感染新冠病毒的直接证据
• BMJ Global Health：居家佩戴口罩或有助于避免COVID-19在家庭成员之间传播
• Reduction of secondary transmission of SARS-CoV-2 in households by face mask use, disinfection and social distancing: a cohort study in Beijing, China
• 从COVID-19患者体内纵向分离强效近生殖细胞系SARS-CoV-2中和抗体 | CellPress论文速递
• Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients
• 与衰老相关的炎症可能会加剧老年人群的COVID-19感染｜文章精选
• Aging immunity may exacerbate COVID-19
• 这四种倾向性评分方法，可有效控制混杂因素
• NEJM | 正式发表！大规模随机对照试验，廉价药地塞米松可以降低新冠患者（有创通气）30%以上的死亡率
• Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
• COVID-19 下的重症监护和急诊医学 | Springer Nature研究集锦
• Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China
• 引领新冠在心肝领域的突破 | 武汉大学李红良等团队首次揭示心脏生物标志物与新冠肺炎的预后关系
• Redefining cardiac biomarkers in predicting mortality of inpatients with COVID-19
• 最新研究 | 2期临床试验发现疫苗安全并能诱导产生免疫应答
• Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
• 陈薇院士新冠疫苗二期出炉：免疫反应显著！各国疫苗争先抢后
• 陈薇团队新冠疫苗二期临床试验结果出炉
• 再取新进展 | 钟南山等团队揭示中国医院访客中SARS-CoV-2的血清阳性率情况
• Serosurvey of SARS-CoV-2 among hospital visitors in China
• 牛津大学新冠疫苗初步实验安全有效！产生强烈免疫反应，效果至少持续两个月
• 一夜间，中英同时发布新冠疫苗临床试验结果：均可引起免疫反应，同时登上《柳叶刀》
• 肺栓塞：COVID-19中低氧血症性呼吸衰竭的另一原因
• Pulmonary embolism: yet another cause of hypoxaemic respiratory failure in COVID-19
• 《柳叶刀》：中英同时发布新冠疫苗临床试验结果，均可引起免疫反应！
• Lancet背靠背 | 振奋人心！陈薇院士领衔的新冠2期临床试验出炉：安全有效
• Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
• 新冠肺炎症状可分为六大类，早期症状能预测未来病情严重性
• 瑞德西韦可抑制人肺细胞的中SARS-CoV-2的复制 | CellPress论文速递
• Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice
• 柳叶刀-感染病学 | COVID-19阳性患者的预后评估
• Assessment of patients who tested positive for COVID-19 after recovery
• 中英同时发布新冠疫苗临床试验结果：均可引起免疫反应，同时登上《柳叶刀》
• 超一半痊愈患者出现多种后遗症，对于新冠病毒，我们还有太多未知
• Nature背靠背 | 羟氯喹从神药到一地鸡毛，在体外都不起作用
• Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2
• Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates
• 最新研究 | 英国疫苗试验初步结果显示，安全且可诱导免疫应答
• 评估氯喹和羟氯喹的抗病毒活性 |《自然》论文
• 《关于印发新型冠状病毒肺炎重症患者呼吸支持治疗和体外膜肺氧合临床应用指导方案（试行）的通知》解读
• 国家卫健委发布《新型冠状病毒肺炎重症患者呼吸支持治疗和体外膜肺氧合临床应用指导方案（试行）》
• 《关于印发新型冠状病毒肺炎重症患者呼吸支持治疗和体外膜肺氧合临床应用指导方案（试行）的通知》解读
• 国家卫健委发布《新型冠状病毒肺炎重症患者呼吸支持治疗和体外膜肺氧合临床应用指导方案（试行）》
• 大规模筛查揭示出潜在的抗SARS-CoV-2药物 |《自然》论文
• Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposin
• NEJM重磅 | 羟氯喹治疗新冠肺炎无效，先前的研究不靠谱
• Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
• Nature/Lancet | 连续取得突破！袁国勇团队发现了众多潜在治疗新冠肺炎的药物，有望应用于临床
• 连发3篇Science/Nature | 秦成峰/王佑春等开发新冠mRNA疫苗：动物试验有效
• A thermostable mRNA vaccine against COVID-19
• Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
• The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity
• 降胆固醇药物能把COVID-19肺炎风险降到普通感冒?
• The SARS-CoV-2 Transcriptional Metabolic Signature in Lung Epithelium
• 应对日益严重的COVID-19危机低收入国家迫切需要呼吸机 ：推荐开源简易呼吸机
• Easier access to mechanical ventilation worldwide: an urgent need for low income countries, especially in face of the growing COVID-19 crisis
• 新冠肺炎病毒受体ACE2的前世今生
• Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor
• Diagnosing SARS-CoV-2 Related Multisystem Inflammatory Syndrome in Children (MIS-C): Focus on the Gastrointestinal Tract and the Myocardium
• 新冠疫苗研发进程：安全性已获证实，有效性尚待确认
• Coronavirus vaccines leap through safety trials — but which will work is anybody’s guess
• 新冠病毒入肺更“伤心”！75%以上康复者出现与心脏病发作相当的长期异常损害
• Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19)
• Is COVID-19 Creating a Generation of Heart Failure Patients?
• 真牛！Nature：华西医院226个氨基酸研发出新冠疫苗！
• A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity
• ChAdOx1 nCoV-19疫苗可预防恒河猴发生COVID-19相关的肺部损伤 |《自然》论文
• Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2
• 单剂量疫苗可保护非人灵长类动物免受SARS-CoV-2的侵袭 |《自然》论文
• Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
• Science：新冠病毒是如何导致新冠肺炎的
• How does SARS-CoV-2 cause COVID-19?
• Nature：牛津疫苗结果正式发表
• 无1期，无2期，无3期的三无新冠疫苗，20几位科学家自己先接种了起来
• Covid-19 vaccine trials are showing promising results. A lot can still go wrong. Covid-19
• COVID-19导致心源性猝死的人群差异性研究
• Genetic susceptibility for COVID-19–associated sudden cardiac death in African Americans
• 国产新冠疫苗发热率高？陈薇院士解读疫苗副作用问题
• 抗新冠病毒的热稳定mRNA疫苗 | CellPress论文速递
• A thermostable mRNA vaccine against COVID-19
• Nature/Lancet | 连续取得突破！袁国勇等团队首次证明新冠病毒可以直接感染神经系统
• SARS-CoV-2 infects human neural progenitor cells and brain organoids
• Science/Nature | 再取新进展！姜世勃等人新冠病毒mRNA疫苗：动物试验有效，有望进一步临床试验
• A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2
• 疫苗可投入大规模生产了！全球首个新冠灭活疫苗生产车间通过生物安全检查
• 南京大学张辰宇团队等通过临床试验证实，金银花可抑制新冠病毒复制，加速患者好转
• Absorbed plant MIR2911 in honeysuckle decoction inhibits SARS-CoV-2 replication and accelerates the negative conversion of infected patients
• Science：另辟蹊径，改造ACE2效果比肩中和抗体
• Engineering human ACE2 to optimize binding to the spike protein ofSARS coronavirus 2
• Science：普通感冒冠状病毒可以教会人体免疫系统识别SARS-CoV-2
• Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans
• Exposure to common cold coronaviruses can teach the immune system to recognize SARS-CoV-2
• 姜世勃团队研发出新型mRNA新冠疫苗
• 2分钟看懂NEJM：COVID-19暴露后应用羟氯喹进行预防
• 谢晓亮：中和抗体有望成为新冠肺炎特效药，可治疗和短期预防​
• 谢晓亮：中和抗体有望成为新冠肺炎特效药，可治疗和短期预防
• Science：面对新冠病毒，孕妇的特殊风险和未知影响
• Why pregnant women face special risks from COVID-19
• 单克隆抗体有望早于疫苗治疗新冠肺炎
• Nature：全球首支新冠疫苗安全性遭质疑
• Russia’s fast-track coronavirus vaccine draws outrage over safety
• SARS-CoV-2候选RNA疫苗在1/2期临床试验诱导免疫应答 | 《自然》论文
• Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults
• 清华免疫所董晨团队等发现COVID-19重症患者细胞免疫缺陷
• Impaired cellular immunity to SARS-CoV-2 in severe COVID-19 patients
• 国产新冠灭活疫苗Ⅰ/Ⅱ期临床试验中期结果公布
• Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes Interim Analysis of 2 Randomized Clinical Trials
• 钙卫蛋白水平升高和异常的髓细胞亚群可用于区分COVID-19轻症与重症患者 | CellPress论文速递
• Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19
• 维生素D可以预防或治疗COVID-19吗？
• Vitamin D for COVID-19 : a case to answer ?
• 新冠疫苗上场之前，抗体疗法能否担起重任？
• Antibody therapies could be a bridge to a coronavirus vaccine — but will the world benefit?
• JAMA | 突破！华中科技大学潘安等团队首次系统公布新冠疫苗不良反应情况
• Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes，Interim Analysis of 2 Randomized Clinical Trials
• 与SARS-CoV-2感染相关的重度儿童多系统炎症综合征 |《自然-医学》论文
• Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection
• 群体免疫来了？无症状或轻症COVID-19恢复期患者强大的T细胞免疫 | Cell Press论文速递
• Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19
• 重大进展 | 陈梦飞博士等揭密新冠肺炎导致嗅觉丧失的原因
• Elevated ACE2 expression in theolfactory neuroepithelium: implications for anosmia and upperrespiratory SARS-CoV-2 entry and replication
• 连发众多研究成果 | 起神效！武汉大学李红良等团队首次发现神药二甲双胍可以减少新冠肺炎患者的心力衰竭等副作用
• Metformin Use Is Associated with Increased Incidence of Acidosis but not Mortality in Individuals with COVID-19 and Pre-existing Type 2 Diabetes
• 为什么受伤的总是肾？《柳叶刀》最新研究证实新冠病毒“嗜肾”！
• Caution on Kidney Dysfunctions of 2019-nCoV Patients
• SARS-COV-2 renal tropism associates with acute kidney injury
• 全球首例！港大袁国勇团队证实有康复者二次感染新冠病毒
• Science头条 | 香港大学研究人员首次发现新冠康复患者可再次被感染
• Some people can get the pandemic virus twice, a study suggests. That is no reason to panic
• 全球首例！袁国勇院士团队证实有新冠康复者二次感染，系康复后在欧洲感染
• 高福团队疫苗制备新方法动物实验成功, 正申请临床试验
• Recombinant SARS-CoV-2 RBD molecule with a T helper epitope as a built in adjuvant induces strong neutralization antibody response
• 不同性别患者对SARS-CoV-2免疫反应的差异 |《自然》论文
• Sex differences in immune responses that underlie COVID-19 disease outcomes
• 中国团队开辟mRNA新冠疫苗全新领域
• A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice
• 研发到哪一步？接种一次管多久？新冠疫苗热点问题，权威解答来了
• 好消息! Moderna新冠疫苗可刺激年长者免疫系统, 产生与年轻人相当抗体水平
• 《Science》子刊详解！开发和评估四种检测新冠病毒抗体的血清学测试方法
• A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations
• COVID-19对神经系统的影响 | CellPress 新冠中心新文
• Effects of COVID-19 on the nervous system
• 柳叶刀-风湿病学 | 探索COVID-19过度炎症反应
• Delving beneath the surface of hyperinflammation in COVID-19
• 2020霍普金斯沙龙VII：详解耶鲁大学唾液新冠检测法-SalivaDirect
• Cell重磅 | 随机对照研究！老年人出院接种卡介苗，可以保护老年人免受感染
• ACTIVATE: RANDOMIZED CLINICAL TRIAL OF BCG VACCINATION AGAINST INFECTION IN THE ELDERLY
• PLoS Pathog：我国科学家开发出一种快速、准确、低成本的COVID-19测试方法
• Development and evaluation of a rapid CRISPR-based diagnostic for COVID-19
• 3万人研究：新冠病毒致死风险0.3%，抗体水平4个月内持平
• Humoral Immune Response to SARS-CoV-2 in Iceland
• The Power of Antibody-Based Surveillance
• 经历细胞因子风暴的COVID-19患者可能不产生记忆B细胞 | CellPress 新冠中心新文
• Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19
• SARS-CoV-2患者康复后被诊断患有糖尿病 |《自然-代谢》论文
• Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection: a case report
• Moderna和辉瑞基因新冠疫苗需超低温保存, 或影响推广计划
• Characteristics and outcomes of 627 044 COVID-19 patients with and without obesity in the United States, Spain, and the United Kingdom
• Lancet | 重大进展！俄罗斯开发的2款新冠疫苗临床试验证明安全及有效激活免疫系统
• Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
• 何种情况下考虑为COVID-19患者施行肺移植治疗？
• When to consider lung transplantation for COVID-19
• T细胞免疫受损与危重症COVID-19无关 | CellPress新冠中心论文速递
• Robust T cell response towards spike, membrane, and nucleocapsid SARS-CoV-2 proteins is not associated with recovery in critical COVID-19 patients
• Nat. Commun. 齐建勋/李学兵/谭文杰/高福研究团队在抗新型冠状病毒药物发现中取得进展
• Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease
• 珍藏版 | Nature子刊综述：新冠疫苗研发的免疫学原理及进展与挑战
• Immunological considerations for COVID-19 vaccine strategies
• 【在线速递】胸腺肽 α1 治疗COVID-19重症患者：一项多中心回顾性队列研究
• Thymosin α1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study
• SARS-CoV-2感染非危重住院患者中病毒排毒时间延长的相关因素以及洛匹那韦/利托那韦治疗的影响
• Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection
• 康复者血浆或可降低COVID-19的严重性 |《自然-医学》论文
• Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study
• Nat Med：单克隆抗体疗法或有望帮助治疗新冠肺炎
• Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
• 【在线速递】重症COVID-19患者血浆中的细胞因子谱与ARDS和脓毒症患者无差异
• Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis
• 支气管镜检查有助于诊断COVID-19吗?
• Does bronchoscopy help the diagnosis in COVID-19 infection?
• 高效的鸡尾酒治疗策略 | Cell Press 新冠中心论文速递
• Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy
• 【Nature】加速发表迄今最好的新冠疫苗综述。直接对比中和抗体，差别一目了然
• SARS-CoV-2 vaccines in development
• 高福一直担心的ADE是什么？Nature子刊重磅综述：ADE效应与新冠疫苗治疗
• Antibody-dependent enhancement andSARS-CoV-2 vaccines and therapies
• 英国“人体挑战试验”明年1月开启，志愿者接种疫苗后将刻意感染新冠病毒
• 为何COVID-19患者经常发生嗅觉丧失
• Why COVID-19 Patients Often Develop Anosmia？
• 用心来抵抗COVID-19 | Springer Nature关注世界心脏日
• Cell Res | 彭小忠/邓宏魁提出了新的治疗新冠肺炎的策略：靶向巨噬细胞
• Effective treatment of SARS-CoV-2-infected rhesus macaques by attenuating inflammation
• 【动向】新冠疫苗上市还要多久：100多种疫苗正在开发中，5种获准早期试用！
• Brussels shoots down Dutch plan to subsidize hydrogen to replace fossil fuels
• 辟谣! 加拿大已成功研发出2天治愈新冠肺炎的特效药?
• Human recombinant soluble ACE2 in severe COVID-19
• 重大进展 | 卞修武/张定宇等发现新冠肺炎患者的新型病理特征
• Pathological changes in the lungs and lymphatic organs of twelve COVID-19 autopsy cases
• JAMA | 再添实证！随机临床试验发现皮质类固醇的使用可以显著降低28天时期危重新冠肺炎患者的死亡率
• Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19,A Meta-analysis
• NEJM | 再取新进展！张锋使用CRISPR技术加速新冠检测
• Detection of SARS-CoV-2 with SHERLOCK One-Pot Testing
• NEJM | 随机双盲对照研究！发现特朗普服用的瑞德昔韦对于缩短新冠肺炎患者恢复时间有效
• Remdesivir for the Treatment of Covid-19 — Final Report
• 新冠病毒鸡尾酒治疗策略深度解读 | CellPress对话科学家
• Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy
• Direct detection of SARS-CoV-2 using CRISPR-Cas13a and a mobile phone
• 柳叶刀：临床试验表明洛匹那韦-利托那韦不能有效治疗新冠患者
• Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
• 洛匹那韦-利托那韦对COVID-19住院患者不是有效治疗方法
• Science：揭示抗体混合物REGN-COV2有望预防和治疗新冠肺炎
• REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters
• 婴儿感染新冠病毒的途径 | 《自然-通讯》论文
• Synthesis and systematic review of reported neonatal SARS-CoV-2 infections
• Science头条 | 全球最大规模的新冠药物临床试验，发现特朗普服用的瑞德昔韦不能降低死亡率
• Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
• Remdesivir and interferon fall flat in WHO’s megastudy of COVID-19 treatments
• Nat Microbiol：中国科学家新发现！抗微生物药物或有望治疗SARS-CoV-2的感染！
• Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters
• 最新研究 | 基于灭活病毒的新冠候选疫苗安全性良好且能诱导免疫反应
• Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
• WHO发表全球最大COVID-19临床试验！瑞德西韦、羟氯喹、洛匹那韦效果甚微。吉利德公司紧急声明！
• Repurposedantiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
• 心脏磁共振成像提示无症状COVID-19患者有心肌损伤
• Competitive Athletes, COVID-19, and CMR Findings
• 儿童COVID-19症状与季节性流感症状的区别
• How Do COVID-19 Symptoms Compare with Seasonal Influenza Symptoms in Children?
• 难以实现完全免疫 | 美国第一例COVID-19再感染病例
• Genomic evidence for reinfection with SARS-CoV-2: a case study
• 华科范雄林教授：新冠肺炎无症状感染者抗体变化规律揭秘！
• Antibody dynamics to SARS‐CoV‐2 in asymptomatic COVID‐19 infections
• Cardiovascular manifestations and mechanisms in patients with COVID-19
• NEJM | 托珠单抗未能减少住院Covid-19患者插管或死亡
• Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
• NEJM | 终槌定音！随机双盲对照研究，发现托珠单抗不能治疗新冠肺炎
• Immunity | 周溪/张定宇/尚游/薛宇/邱洋合作揭示新冠病毒肺炎疾病标志物与致病机制
• Plasma Proteomics Identify Biomarkers and Pathogenesis of COVID-19
• 姜世勃 Nature子刊：借鉴过去，关注新冠疫苗的未来
• Learning from the past: development of safe and effective COVID-19 vaccines
• Prospects for a safe COVID-19 vaccine
• 最新研究发现：神药阿司匹林可降低新冠患者死亡率
• Aspirin Use is Associated with Decreased Mechanical Ventilation, ICU Admission, and In-Hospital Mortality in Hospitalized Patients with COVID-19
• COVID-19可影响心脏，病毒对心脏有明显趋向性｜Science新冠专题
• COVID-19 can affect the heart
• 重大进展 | 同济大学左为团队研究揭示新冠重症患者肺部干细胞可参与肺损伤修复
• Single-cell analysisidentified lung progenitor cells in COVID-19 patients
• 与重症相关的SARS-CoV-2免疫应答 |《自然-微生物学》论文
• Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
• 利用肺和结肠类器官筛选抗新冠病毒的药物 | 《自然》论文
• Identification of SARS-CoV-2 Inhibitors using Lung and Colonic Organoids
• 新冠患者呼吸衰竭与高血压之间的联系：来自COVID-19患者的证据
• The liaison between respiratory failure and high blood pressure: evidence from COVID-19 patients
• Cell Research:新冠肺炎治疗的新策略
• COVID-19流行期间眼科急诊手术的实践经验| Graefe's Archive
• Practical experience on emergency ophthalmic surgery during the prevalence of COVID-19
• COVID-19流行期间眼科急诊手术的实践经验| Springer Journal
• 医务工作者如何降低感染新冠肺炎的风险？
• Knowledge, attitude, and practice regarding COVID-19 among healthcare workers in Henan, China
• The BMJ:COVID-19：长期佩戴FFP3口罩与皮肤损伤【国内外读者来信】【2020年第8期】
• Covid-19: skin damage with prolonged wear of FFP3 masks
• Cell：令人关注！大约20%的新冠肺炎患者在三到四个月内维持抗病毒抗体产生
• Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production
• Study uncovers subset of COVID-19 patients who recover quickly and sustain antibodies
• 2分钟看懂NEJM：瑞德西韦治疗COVID-19——ACTT-1试验最终结果
• 针对新冠肺炎的预存免疫力：T细胞的故事
• Covid-19: Do many people have pre-existing immunity?
• 首次公布 | 市值增加2000亿！辉瑞等公司3期临床中期有效性分析显示新冠疫苗90%有效，特朗普表示这是个好消息
• Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
• A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates
• 危重COVID-19患者的消化道并发症
• Gastrointestinal Complications in Critically Ill Patients with COVID-19
• 有效性超90%？关于辉瑞新冠疫苗，科学家怎么看？
• What Pfizer's landmark COVID vaccine results mean for the pandemic
• JAMA | 重大发现！0恶化，首次发现抗抑郁药氟伏沙明可显著降低轻症新冠肺炎患者临床恶化
• Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19,A Randomized Clinical Trial
• 新冠快速康复者体内持续产生抗SARS-CoV-2病毒抗体 | Cell Press新冠中心论文速递
• Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production
• 【Science】14.7%的普通感冒患者出现抗新冠病毒抗体！
• Preexisting and de novo humoral immunity to SARS-CoV-2 in humans
• Moderna疫苗保护率94.5%，中国疫苗何时报喜？
• Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy
• 研究发现提高COVID-19诊断准确度的特异性抗体
• Detailed Study Finds Accurate Antibody “Fingerprint” for COVID-19
• 康复患者体内的新冠病毒交叉中和抗体反应 |《自然-微生物学》论文
• Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals
• NC | 黄超兰团队与高福团队等合作发现早期新冠病毒感染主要为免疫抑制或存在“两阶段”机制
• Immune suppression in the early stage of COVID-19 disease
• 有效性超94%！Moderna疫苗三期试验刷新“抗疫”新纪录
• COVID vaccine excitement builds as Moderna reports third positive result
• 【观点】想降低感染新冠的风险吗？除了疫苗，更简单的方式是多睡一会儿
• Want to reduce your COVID-19 risk? You need to sleep more.
• The immuno-oncological challenge of COVID-19
• 疫苗捷报连连 高福：相信我，中国疫苗也非常有效
• 重大研究发现！mRNA疫苗 vs 重组蛋白疫苗，哪种疫苗更胜一筹？​
• SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generatio
• 嗅觉失灵意味着什么？马上了解！
• Sixty seconds on . . . parosmia
• SARS-CoV-2感染和症状发作后的血清学特征
• Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset
• The BMJ：新研究表明恢复期血浆在减少新冠肺炎死亡率或进展为重症方面未反映出有效性
• Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
• 突破！向宽辉/童贻刚/周乙华/施一合作首次发现母乳可有效阻断新冠病毒感染
• The effect of whey protein on viral infection and replication of SARS-CoV-2 and pangolin coronavirus in vitro
• 最新研究 | 中国候选疫苗具备安全性，且可储存在2~8摄氏度的标准冰箱中
• Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
• 新英格兰医学杂志重磅：康复者血浆治疗对改善新冠患者预后没有帮助
• A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
• 新冠病毒感染和胆固醇之间的关联提示新冠肺炎疗法的新可能 |《自然-代谢》论文
• HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry
• 北大首次发现母乳可有效阻断新冠病毒感染
• 牛津新冠疫苗2期临床试验：在健康老年人群中安全且能够诱导免疫应答
• Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
• Use of dialysis, tracheostomy, and extracorporeal membrane oxygenation among 240,392 patients hospitalized with COVID-19 in the United States
• COVID-19诱导的急性呼吸窘迫综合征的发病机制：对衰老人群的影响
• Pathogenesis of COVID-19-induced ARDS: implications for an ageing population
• 面对争议：白介素-6和COVID-19细胞因子风暴综合征
• Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome
• SARS-CoV-2或通过鼻子进入大脑 |《自然-神经科学》论文
• Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19
• Nat Neuro丨新冠病毒或通过鼻子进入大脑
• 去年12月美国有无新冠病毒感染？美国疾控中心研究引发争论
• Serologic testing of U.S. blood donations to identify SARS-CoV-2-reactive antibodies
• 保护效力提高近10倍！中国科学家探索新冠病毒抗体鸡尾酒疗法
• Rational Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-SARS-CoVs Protection
• Structure-based development of human antibody cocktails against SARS-CoV-2
• 高福院士团队新冠病毒重组蛋白亚单位疫苗启动Ⅲ期临床试验
• The BMJ: 研究显示年轻患者不一定能逃脱最严重的流行病
• Long covid: Damage to multiple organs presents in young, low risk patients
• 找到有效候选疫苗后，COVID-19疫苗试验是否能继续合乎伦理？｜Science精选
• COVID-19 vaccine trial ethics once we have efficacious vaccines
• Nature子刊 | 重大进展！黄超兰/高福等团队合作发现早期新冠病毒感染主要为免疫抑制并或存在“两阶段”机制
• 背靠背两篇Cell Res：王祥喜/李兰娟等开发新冠鸡尾酒疗法，更好阻断病毒入侵
• The BMJ：关节炎药物可改善新冠肺炎危重患者治疗效果的研究报告
• Covid-19: Critically ill patients treated with arthritis drug tocilizumab show improved outcomes, researchers report
• 中山大学张辉团队开发新冠病毒新型纳米颗粒疫苗 | Cell Press新冠中心论文速递
• Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses
• 如何区分是COVID-19还是H1N1导致的急性呼吸窘迫综合征？
• Comparison of Hospitalized Patients With ARDS Caused by COVID-19 and H1N1
• 应用托珠单抗治疗COVID-19的4项研究总结
• Does Tocilizumab Have a Role in the Treatment of COVID-19?
• The BMJ：世卫组织更新指南称，尚无明确证据证明瑞德西韦对抗新冠肺炎的有效性
• A living WHO guideline on drugs for covid-19
• Science深度报道｜踏出国门的中国新冠疫苗
• Antibody profiling and prevalence in US patients during the SARS-CoV2 pandemic
• 新冠疫苗试验喜讯连连？牛津大学论文：莫急
• Oxford COVID vaccine paper highlights lingering unknowns about results
• 英国已批准了COVID疫苗-这是科学家现在想知道的​
• The UK has approved a COVID vaccine — here’s what scientists now want to know
• 一网打尽：冠状病毒家族治疗靶点首次被确定
• Genetic screens identify host factors for SARS-CoV-2 and common cold coronaviruses
• NEJM | 正式发布！辉瑞等公司研制的新冠疫苗有效性为95%，但是要注意其面瘫等副作用
• Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
• 辉瑞疫苗通过FDA认证，新冠疫情真的能被抑制吗？
• 新冠病毒感染引起的谵妄会导致失智吗？
• Could COVID delirium bring on dementia?
• Science新冠合集｜JAK抑制剂巴瑞替尼表现出对抗细胞因子风暴的良好前景
• JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality
• [Science新冠合集｜SARS-CoV-2病毒T细胞免疫依然有许多未解之谜])(https://mp.weixin.qq.com/s/yVtDxPhQg9XX3GUjBq574Q)
• The known unknowns of T cell immunity to COVID-19
• 首项3期试验公布结果，表明牛津疫苗可安全有效地抗击新冠
• Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
• 美国批准首款新冠疫苗紧急使用授权，抗疫进入新阶段
• US authorization of first COVID vaccine marks new phase in safety monitoring
• 静动脉体外膜肺氧合用于治疗新冠肺炎并发症
• Cardiovascular Collapse in COVID-19 Infection: The Role of Venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO)
• Science长文 | 中国的新冠疫苗研发始末，在艰难中获得成功！
• China's vaccine gambit
• 2分钟看懂NEJM：老年人接种SARS-CoV-2 mRNA疫苗的1期研究
• Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
• 恢复期血浆治疗感染SARS-CoV-2的重症患者的疗效研究
• Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
• Science新冠｜根据疫苗开发经验，对新冠疫苗进行全面安全性试验
• Ensuring vaccine safety
• 北卡州立大学谢德玉教授研究表明 绿茶巧克力葡萄可以对抗新冠病毒
• Science关注：辉瑞公司mRNA新冠疫苗会触发罕见的严重过敏反应
• 武汉全民SARS-CoV-2免疫球蛋白抗体检测结果
• Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: part of the city-wide massive testing campaign
• NEJM | 免疫系统的一场混战！细胞因子风暴如何成为疾病的“夺命帮凶”
• Cytokine Storm
• Nature | 新冠疫苗的前途与“钱”途
• The lightning-fast quest for COVID vaccines — and what it means for other diseases
• 新冠肺炎: 接触后抗体保护试验
• Covid: Post-exposure antibody protection trialled
• COVID-19和气胸：一项多中心回顾性病例系列研究
• COVID-19 and pneumothorax: a multicentre retrospective case series
• 嗅觉神经上皮中ACE-2的高度表达：对嗅觉和上呼吸道SARS-CoV-2进入和复制的影响
• Elevated ACE-2 expression in the olfactory neuroepithelium: implications for anosmia and upper respiratory SARS-CoV-2 entry and replication
• 特异性IgA在重症COVID-19新冠肺炎发病中的重要作用
• Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients
• 微生物所高福院士和戴连攀研究员受邀在Nature Reviews Immunology发表新冠疫苗靶点综述论文
• Viral targetsfor vaccines against COVID-19
• 为什么美国新冠疫苗突然走得更快了？中国疾控中心主任高福回应
• 高福回应：为什么西方不做灭活疫苗？为什么美国新冠疫苗突然走得更快了？
• 《自然》：新冠疫苗的闪电开发速度将深刻改变疫苗科学的未来
• The lightning-fast quest for COVID vaccines — and what it means for other diseases
• 新冠疫苗上市了，WHO专家为何仍坚持开展安慰剂对照试验
• Placebo-Controlled Trials of Covid-19 Vaccines — Why We Still Need Them
• 今天，中国新冠病毒疫苗获批上市！
• 我国首个新冠疫苗获批上市！79.34%的保护力意味着什么？
• Nature拳头综述（IF=40） | 高福系统总结全球新冠疫苗技术路线和研究靶点
• 病毒“塞鼻孔”！自愿染新冠， 2500人争当小白鼠：光荣病死
• 中国疾控中心周刊：上海发现首例来自英国的变异新冠病毒感染病例
• Notes from the Field: The First Case of New Variant COVID-19 Originating in the United Kingdom Detected in a Returning Student — Shanghai Municipality, China, December 14, 2020
• 快如闪电！新冠疫苗的研发速度是如何实现的？
• 2分钟看懂NEJM：BNT162b2 COVID-19疫苗的安全性和有效性
• Safety and Efficacy of the BNT162b2 Covid-19 Vaccine
• 还在犹豫是否接种？先看看国药集团灭活疫苗的秘密
• 每支都有“身份证”！探访新冠病毒疫苗生产基地……
• 《新英格兰医学杂志》综述：新冠疫苗的安全性
• Maintaining Safety with SARS-CoV-2 Vaccines
• Science新冠｜感染新冠病毒后，抗体免疫反应能持续多久？
• Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome
• 低剂量的吐根碱可以作为抗新冠病毒的潜在药物 | Molecular Biomedicine | 中科院刘青松团队
• Low dose of emetine as potential anti-SARS-CoV-2 virus therapy: preclinical in vitro inhibition and in vivo pharmacokinetic evidences
• Cell Metabolism | 突破！武汉大学李红良等团队首次解决了全球糖皮质激素治疗新冠用药难题，有望降低新冠患者死亡率
• The neutrophil-to-lymphocyte ratio determines clinical efficacy of corticosteroid therapy in patients with COVID-19
• 新冠疫苗全民免费，但5类人暂缓接种！关于疫苗的7大事项，你得了解
• 新冠病毒疫苗有必要接种吗？权威指南来了
• mRNA疫苗爆出严重过敏反应，《新英格兰医学杂志》：不会产生永久性损害
• Lancet | 2021年首秀！曹彬/张定宇/王建伟等首次系统揭示新冠出院患者的情况：疲劳或肌肉无力等较常见
• 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
• 《柳叶刀》最新研究：金银潭出院新冠患者，超7成半年后仍有健康影响
• 最新研究 | 大部分COVID-19出院患者在发病6个月后仍有至少一个症状
• 重磅丨《柳叶刀》刊登中国专家重要研究结果：COVID-19住院患者发病后半年76%仍存在至少一个症状……
• DISINFECTION MEASURES AND COVID-19
• 《柳叶刀》最新研究：金银潭出院新冠患者，超7成半年后仍有健康影响
• 神奇案例！癌症晚期患者感染新冠后，肿瘤竟然消失了……
• Sars-cov-2-induced remission of Hodgkin lymphoma
• 康复的新冠患者，七成半年后可能仍有不良症状
• 还在纠结打不打新冠病毒疫苗？看完就明白了
• The BMJ:​COVID-19并非大号流感，防控切不可松懈！
• Comparative evaluation of clinical manifestationsand risk of death in patients admitted to hospital with covid-19 and seasonalinfluenza: cohort study
• BioNtech新冠疫苗可抗多个变种 推出新疫苗仅需6周
• 再添实证 | 首都医科大学等多单位合作，发现新冠患者康复后可能会发生再次感染的风险，即使是产生了中和抗体
• COVID-19 reinfection in the presence of neutralizing antibodies
• 巴西公布科兴新冠疫苗总体有效率50.38%
• 辉瑞疫苗真实有效率只有29%？这个质疑很荒谬
• Peter Doshi: Pfizer and Moderna’s “95% effective” vaccines—let’s be cautious and first see the full data
• 科兴疫苗巴西最新数据：新冠预防有效率调低到50.34%！
• Indonesia approves China's Sinovac vaccine as infections surge
• Brazil researchers report more modest 50.4% efficacy for China’s CoronaVac
• 对比中美英等七国疫苗接种现状，谁正在领跑？
• Metabolic Healthy Obesity, Vitamin D Status, and Risk of COVID-19
• 新冠病毒再感染需要警惕吗？
• COVID reinfections are unusual — but could still help the virus to spread
• 姜世勃：广谱抗冠疫苗和药物是防控现在和未来新冠疫情的最佳选择
• 新免疫策略可预防新冠和其他威胁人类健康的冠状病毒｜Science新冠
• Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice
• 反转：新冠病毒“治愈”癌症，不是医学奇迹！
• 维生素D和新冠的关系：为什么会存在争议？
• Vitamin D and COVID-19: why the controversy?
• COVID-19患者出院并不意味着战斗结束
• The Fight Doesn't End Once COVID-19 Patients Are Discharged
• 新冠病毒引起的嗅觉和味觉失灵是怎么回事？
• COVID’s toll on smell and taste: what scientists do and don’t know
• 免疫中的生物学性别差异会令男性更易于感染重症COVID-19吗？｜一周精选
• Sex differences in immune responses
• 《自然》：“流氓抗体”是导致新冠患者器官长期损伤的原因
• Rogue antibodies could be driving severe COVID-19
• 生下来就得新冠！我到底做错了什么？
• SARS-CoV-2 can infect the placenta and is not associated with specific placental histopathology: a series of 19 placentas from COVID-19-positive mothers
• Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study
• 情报研发 | 新冠通过神经系统影响嗅觉和味觉的研究进展 【中国科讯】 中国科讯
• 被遗忘的新冠幸存者 | BMC Health Services Research
• Persistent symptoms after Covid-19: qualitative study of 114 “long Covid” patients and draft quality principles for services
• 静-静脉体外膜氧合治疗COVID-19：来自英国的病例系列
• Veno-venous extracorporeal membrane oxygenation in coronavirus disease 2019: a case series
• 新冠重症患者的抗病毒反应受损 |《自然》论文
• Global absence and targeting of protective immune states in severe COVID-19
• Nature | 新冠重症患者的抗病毒反应受损
• 新冠疫苗“催熟”mRNA技术，将极大促进癌症和HIV疫苗研发
• 新冠 “复阳” 之谜：我们解开了多少？还有多少不知道？
• 连花清瘟胶囊抗新冠肺炎药理活性成分取得新进展
• The BMJ | 尚无证据表明维生素D可预防和治疗新冠肺炎
• Covid-19: Evidence is lacking to support vitamin D’s role in treatment and prevention
• Nat Comm | 黄昊/张国良合作在抗新冠病毒药物开发和抑制剂作用机制上获得进展
• The Complex Structure of GRL0617 and SARS-CoV-2 PLpro Reveals a Hotspot For Antiviral Drug Discovery
• Trends in Clinical Symptoms of Novel Coronavirus Disease (COVID-19) in the Northwest of Iran
• 部分新冠重症的“元凶”可能找到了！
• Rogue antibodies could be driving severe COVID-19
• 全球首款 mRNA 新冠疫苗背后的中国力量
• 大脑是新冠病毒重点攻击器官，研究发现病毒可感染人类神经元
• Neuroinvasion of SARS-CoV-2 in human and mouse brain
• COVID-19：由欧洲呼吸学会和美国胸科学会联合工作组在入院及出院后阶段进行肺康复的临时建议
• COVID-19: interim guidance on rehabilitation in the hospital and post-hospital phase from a European Respiratory Society- and American Thoracic Society-coordinated international task force
• 浙大教授提醒：注射新冠疫苗后，还要补充营养
• 康希诺与陈薇团队联合研发的腺病毒新冠疫苗，3期试验获积极结果
• 超越瑞德西韦：在临床前模型中，抗病毒药物plitidepsin抑制新冠肺炎的效果更优｜Science新冠专题
• Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A
• 特别关注丨全球期待已久的新冠疫苗终于来了，为何大家的接种意愿差强人意？有哪些担心？接种后的不良反应是什么？
• 高福最新研究：国产新冠疫苗对超强变异株依然有效！
• Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines
• 混合接种新冠疫苗能增强免疫反应吗？
• Could mixing COVID vaccines boost immune response?
• 2分钟看懂NEJM：mRNA-1273 SARS-CoV-2疫苗的效力和安全性
• Efficacy and Safety of mRNA-1273 SARS-CoV-2 Vaccine
• 综述新冠病毒的感染机制以及最新的治疗和预防策略 | Molecular Biomedicine | 四川大学马学磊团队
• Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines
• 40名患者的血清结果显示，BioNTech-辉瑞mRNA疫苗对英国新冠病毒变异株极为有效｜Science新冠专题
• Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera
• The BMJ∣英国孕妇和哺乳期妇女现在可以接种新冠肺炎疫苗
• Covid-19: Breastfeeding women can have vaccine after guidance turnaround
• 12个月研制出8种疫苗，科学界是如何做到的？ | Cell Press 新冠中心报道
• How to develop 8 vaccines in 12 months
• Nature 盘点 ：针对新冠病毒新变种，如何设计COVID-19疫苗
• How to redesign COVID vaccines so they protect against variants
• Science｜新冠疫苗进展顺利，但治疗效果喜忧参半
• Two new vaccines deliver good and bad news for the pandemic
• BNT162b2疫苗可以中和三种新冠病毒变种 |《自然-医学》论文
• Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera
• 单针疫苗！陈薇团队终于公布三期数据
• 世卫在武汉新冠溯源研究结果公布
• Nature子刊 | 新发现！马麦卷/张纪岩揭示新冠患者（感染3个月后）对新冠病毒的持久抗体产生和T细胞应答
• Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19 patients three months after infection
• 疫苗麦片？科学家使得疫苗传输更加方便
• Scientists Invented Freeze-Dried Vaccines That Can Be Rehydrated on Demand
• 2分钟看懂NEJM：不同抗体状态医护人员的SARS-CoV-2感染率
• Incidence of SARS-CoV-2 Infection in Health Care Workers by Antibody Status
• A Clinical Analysis of Extrapulmonary Complications in Novel Coronavirus Pneumonia Patients
• Recommendations and Clinical Guidance for Children with Metabolic-associated Liver Disease during the COVID-19 Pandemic
• Human intestinal organoids recapitulate enteric infections of enterovirus and coronavirus
• SARS-CoV-2 reinfection by the new Variant of Concern (VOC) P.1 in Amazonas, Brazil
• 一年后，曾在风口浪尖的新冠血浆疗法逐渐明晰
• (A Little) Clarity on Convalescent Plasma for Covid-19
• 2020年生物制药领域交易一览 | BioPharma Dealmakers 2020年12月刊
• Biopharma deals of 2020 break through
• 重大发现！武汉大学徐可/蓝柯揭示流感病毒的感染，可增强新冠病毒的感染力
• Coinfection with influenza A virus enhances SARS-CoV-2 infectivity
• Cell Res | 重大发现！武汉大学徐可/蓝柯揭示流感病毒的感染，可增强新冠病毒的感染力
• Differences in Clinical Characteristics and Chest Images between Coronavirus Disease 2019 and Influenza-Associated Pneumonia
• NEJM：英国主动感染新冠病毒试验的科学意义和局限性
• Accelerating Development of SARS-CoV-2 Vaccines — The Role for Controlled Human Infection Models
• 故意让人感染新冠病毒，英国批准新冠挑战试验：这是疫苗研发的必需代价吗？
• 马斯克豁出4300员工，参与新冠研究，论文登上Nature子刊
• Discrete SARS-CoV-2 antibody titers track with functional humoral stability
• 华西医院唐向东教授团队：新冠疫苗接种当晚尤其需要充足睡眠
• Advice for COVID-19 vaccination: get some sleep
• 胸腺法新（Ta1）COVID-19年度研究精选
• 国药疫苗vs. 辉瑞疫苗，谁与争锋？
• NEJM发表mRNA新冠疫苗接种真实世界研究；效力与临床试验结果一致
• BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
• 牛津新冠疫苗试验最新分析：两剂间隔3个月接种比间隔6周效力更高
• Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
• Rational Design of a Pan-Coronavirus Vaccine Based on Conserved CTL Epitopes
• NC|黄忠/丛尧/谢幼华/邓强成功研发针对新冠病毒的中和抗体鸡尾酒疗法
• Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections
• 2分钟看懂NEJM：地塞米松治疗COVID-19
• Dexamethasone and Covid-19
• 国内首个单针接种的新冠疫苗来了！安全性、有效性如何？白岩松专访陈薇院士
• 陈薇院士揭秘：国内首个单针接种新冠疫苗效果如何？
• 国内首个单针接种新冠疫苗有效性如何？白岩松专访陈薇
• 陈薇院士专访：中国疫苗研发位于世界第一方阵，毋庸置疑
• 国内首个单针接种的新冠疫苗来了！安全性、有效性如何？陈薇院士这样说
• 焦点：超6万名已注射新冠疫苗的副作用追踪
• Changes in SARS CoV-2 Seroprevalence Over Time in Ten Sites in the United States, March – August, 2020
• How to test SARS-CoV-2 vaccines ethically even after one is available
• 香港大学重磅：新冠疫苗作用被高估，无法抑制病毒在上呼吸道的侵染
• Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies
• 高福领衔研发疫苗在乌兹别克斯坦被批准紧急使用
• Cell：入院第17-23天是新冠病情严重程度的“分水岭” | Cell Press新冠中心论文速递
• Time-resolved Systems Immunology Reveals a Late Juncture Linked to Fatal COVID-19
• Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents
• MDPI Vaccines | 新冠之役——关于细胞免疫接种预防呼吸道病毒的思考
• Harnessing Cellular Immunity for Vaccination against Respiratory Viruses
• 重磅！陈薇、钟南山团队传来最新消息！
• 黄爱龙教授团队发现新冠病毒变异株降低中和抗体敏感性
• Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies
• 防疫科普｜关于新冠疫苗，你需要知道这些！
• Lancet子刊（IF=22）| 连续取得进展！复旦大学余宏杰课题组在新冠肺炎血清流行病学领域取得重要进展
• Serologicalevidence of human infection with SARS-CoV-2: a systematic review andmeta-analysis
• 芬兰研发出鼻喷式新冠疫苗
• 复旦大学余宏杰课题组在新冠肺炎血清流行病学领域取得重要进展
• 病毒学家之争：延迟注射第二针疫苗有没有危害
• Strengthen the Immune System with Nutrients to Overcome COVID-19 Infection
• 阿斯利康疫苗惊曝“血栓门”？全球多国紧急叫停！世卫已展开调查
• 新冠疫苗哪家强？
• Plos Pathogens：大多数人天生就可以抵抗SARS-CoV-2
• Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors
• 单针接种新冠疫苗什么时候能打？答案来了
• 阿斯利康疫苗要“凉”？欧洲18国紧急叫停，是否致死尚无定论
• 【在线速递】Covid-19重症肺炎患者恢复期血浆治疗的一项随机对照试验
• 新冠病毒突变背景下：人体挑战实验是检验疫苗有效性的最佳方法之一
• Human challenge trials to assess the efficacy of currently approvedCOVID-19 vaccines against SARS-CoV-2 variants
• 我国自主知识产权抗SARS-CoV-2候选新药DC402234启动美国I期临床试验
• 中国生物第三款四价流感疫苗获批上市
• 全球知名疫苗专家呼吁：立即停止大规模新冠疫苗接种
• SARS-CoV-2 and COVID-19: An Evolving Review of Diagnostics and Therapeutics
• Cell | 姜世勃/杨海涛首次发表具有针对高致病性病毒的共同靶标的抗病毒药的综述
• Antivirals with common targets against highly pathogenic viruses
• 姜世勃、杨海涛Cell｜抗病毒药物全面综述、人类应如何应对下一次新发病毒的流行？
• 华科重磅成果：新冠感染严重影响男性性能力
• Impaired spermatogenesis in COVID-19 patients
• 首个三剂新冠疫苗来了！国内获批的5款疫苗都有什么不同？
• 《柳叶刀》子刊：华科团队发现，新冠感染严重影响男性性能力
• 疫苗宣布“安全”，又有人接种后死亡？确定阿斯利康疫苗与血栓存在联系
• 中科院微生物所严景华研究员参加国务院联防联控机制新闻发布会介绍新冠肺炎重组蛋白疫苗情况
• NEJM：医护人员接种新冠疫苗后患病率骤降，但仍有感染
• 最新研究 | 重复感染的情况罕见，但在65岁以上人群中更常见
• Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study
• 2020年抗新冠病毒药物研发热点回眸
• 祸不单行|流感助虐新冠：研发流感-新冠通用疫苗刻不容缓
• Double insult: flu bug enhances SARS-CoV-2infectivity
• 可怕！新冠轻度患者康复后也有后遗症！
• Recovered not restored: Long-term health consequences after mildCOVID-19 in non-hospitalized patients
• 首版新冠疫苗接种指南发布！速览
• 关于接种新冠疫苗后单侧腋窝淋巴结肿大的研究
• Unilateral axillary Adenopathy in the setting of COVID-19 vaccine
• 新冠病毒疫苗接种技术指南（第一版）
• 死亡率高、病程长：新冠肺炎为何比其他肺炎更危险？
• Signs of self-sustained inflammatory circuits in severe COVID pneumonia
• 新冠病毒疫苗接种技术指南（第一版）
• 临床疑似COVID-19患者采用不同检测法的效果对比
• Diagnostic performance between CT and initial real-time RT-PCR for clinically suspected 2019 coronavirus disease (COVID-19) patients outside Wuhan, China
• 评估恢复性血浆对变种新冠病毒的中和潜力 |《自然》论文
• Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
• 图解 | 新冠病毒疫苗接种技术指南（第一版）
• 法国证实阿斯利康疫苗可造成罕见血栓
• 国家卫健委最新明确，这5类人不宜接种新冠疫苗！误读全解→
• SARS-CoV-2感染恢复期患者的残留症状和肺功能下降
• Residual symptoms and lower lung function in patients recovering from SARS-CoV-2 infection
• 肝素结合蛋白水平与严重COVID-19中的病情加重和多器官损伤相关
• Heparin-binding protein levels correlate with aggravation and multiorgan damage in severe COVID-19
• 哪些人不能打新冠疫苗？看这一篇就知道了！
• 【同心守护】九图了解新冠疫苗接种技术指南
• 【你问我答1】新冠病毒疫苗接种技术指南（第一版）
• 【你问我答2】新冠病毒疫苗接种技术指南（第一版）
• 【你问我答3】新冠病毒疫苗接种技术指南（第一版）
• 【你问我答4】新冠病毒疫苗接种技术指南（第一版）
• 图解 | 新冠病毒疫苗接种问答（一）
• 图解 | 新冠病毒疫苗接种问答（二）
• 图解 | 新冠病毒疫苗接种问答（三）
• 图解 | 新冠病毒疫苗接种问答（四）
• 图解 | 新冠病毒疫苗接种问答（五）
• 中国疾控中心新冠病毒疫苗接种问答
• 中科院微生物所新冠疫苗：临床试验志愿者接种近一年后仍有抗体
• 新冠疫苗接种海报发布啦！（内附下载链接）
• Nat. Med.两连发：辉瑞mRNA疫苗到底有没有效
• Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine
• 哪些人不能打新冠疫苗？看这一篇就知道了！
• Determining the cutoff points of the 5C scale for assessment of COVID-19 vaccines psychological antecedents among the Arab population: A multinational study
• Community Attitudes Towards Covid-19 Vaccination
• Low circulation of Influenza A and coinfection with SARS‐CoV‐2 among other respiratory viruses during the COVID‐19 pandemic in a region of southern Brazil
• “疫苗接种犹豫”？中疾控专家六个回答必看
• NEJM发布国药和科兴疫苗对英国、南非突变株中和效力数据
• Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization
• 新冠肺炎疫情期间公共场所应如何科学消毒
• 《柳叶刀》子刊：最新研究发现，超1/3新冠患者脑部出现问题
• 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records
• 代谢综合征和非酒精性脂肪性肝炎患者是否更易患上COVID-19？
• The incidence of COVID-19 in patients with metabolic syndrome and non-alcoholic steatohepatitis: A population-based study
• 抗寄生虫药物或能预防新冠病毒诱导的肺部细胞融合 |《自然》论文
• Drugs that inhibit TMEM16 proteins block SARS-CoV-2 Spike-induced syncytia
• Nature | 抗寄生虫药物或能预防新冠病毒诱导的肺部细胞融合
• 锤了！79人血栓、19人死亡，官方确认阿斯利康疫苗副作用或确实存在
• Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February
• 新冠疫苗你打了吗？研发我来，接种靠你们了 | 戴连攀
• 柳叶刀-微生物 | 借鉴COVD-19经验，改善结核诊断
• Learning from COVID-19 to reimagine tuberculosis diagnosis
• 万万没想到，美国新冠疫苗多到打不完了
• 新冠疫苗的不良反应有多严重？
• Why is it so hard to investigate the rare side effects of COVID vaccines?
• Nature | 抗寄生虫药物或能预防新冠病毒诱导的肺部细胞融合
• Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers
• 苏黎世联邦理工学院Jing Wang团队ACS Nano：基于光热与信号放大的LSPR新冠病毒检测方法
• Thermoplasmonic-Assisted Cyclic Cleavage Amplification for Self-Validating Plasmonic Detection of SARS-CoV-2
• 三重奏！国药集团中国生物研究院重组新冠病毒疫苗获批临床试验
• 疾控中心新作：史上最强灭活疫苗临床数据公布
• Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine (KCONVAC) in Healthy Adults: Two Randomized, Double-blind, and Placebo-controlled Phase 1/2 Clinical Trials
• 中国疾控中心主任高福回应“中国疫苗保护率低？”
• Gut | 再取新进展！浙江大学李兰娟团队发现肠道菌群的变化与新冠患者预后的关系
• Six-month follow-up of gut microbiota richness in patients with COVID-19
• 科兴灭活疫苗真实世界保护效力数据发布，来自突变病毒株流行的巴西
• 柳叶刀-感染病学 | 应从现在起推行新冠病毒抗原快速诊断检测
• Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy study
• 科兴疫苗超详细保护力数据出炉！对预防重症COVID-19保护率为100%！
• NEJM两篇重磅！解密新冠疫苗血栓形成机理
• Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
• Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
• 重组新冠疫苗上新！新在哪？
• 中国疫苗保护率低？纠正疫苗接种「一刀切」
• Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany
• 首支国产mRNA新冠疫苗接近III期临床，将实现中国mRNA疫苗“零”突破
• 腺病毒载体疫苗遭遇“滑铁卢”, 多国暂停接种
• Nature关注:疫苗为何导致血栓？
• How could a COVID vaccine cause blood clots? Scientists race to investigate
• 什么是最好的新冠疫苗？
• 最强灭活新冠疫苗：中和抗体是康复者的2.7倍，国内第一，全球第四
• 也谈强生、阿斯利康疫苗被暂停使用后可能引发的系列问题
• Moderna CEO最新采访：如果爆发新疫情，20天左右就能开发出疫苗
• 打疫苗第一针没事，第二针就安全吗？搞懂疫苗不良反应，看这篇就够了
• 谁是牛津疫苗的金主爸爸？研发一款疫苗到底需要多少钱？
• Who funded the research behind the Oxford-AstraZeneca COVID-19 vaccine? Approximating the funding to the University of Oxford for the research and development of the ChAdOx vaccine technology
• 惊人！以色列研究：南非发现的变种病毒，突破辉瑞疫苗防御的可能性大幅提高
• S. African Covid variant better at bypassing Pfizer jab: Israeli study
• 【防疫宣传】一图看懂！新冠病毒疫苗知识18问答
• 国产新冠疫苗首个最大规模真实世界研究结果发布：科兴有效性 67%
• 柳叶刀-呼吸病学 | 既往感染新冠的年轻人仍面临再感染风险
• SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study
• 疫苗产量全球第一的印度，自己快打不上新冠疫苗了
• 柳叶刀子刊：武汉大学曾宪涛团队探讨新冠复阳特征及危险因素
• A systematic review and meta-analysis of discharged COVID-19 patients retesting positive for RT-PCR
• CDC周报：接种疫苗后仍感染的原因找到了
• 重大进展！张凯/唐琪琳/王朋倩首次发现针灸对新冠患者治疗可能产生积极作用的潜在机理
• Is acupuncture effective in the treatment of COVID-19 related symptoms? Based on bioinformatics/network topology strategy
• 国药新冠疫苗安全数据出炉：未见严重不良反应
• Clinical Course and Mortality of Stroke Patients With Coronavirus Disease 2019 in Wuhan, China
• 逾50万人次接种，国药中国生物新冠灭活疫苗安全性数据发布
• 新冠疫苗和血栓确定相关吗？五问五答
• COVID vaccines and blood clots: five key questions
• 江苏144人参与！瑞mRNA疫苗中国人群I期临床数据出炉！
• Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study
• 2分钟看懂NEJM：托珠单抗用于治疗COVID-19肺炎
• Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
• 重组新冠病毒疫苗Ⅰ/Ⅱ期临床试验启动
• 解读│15例严重血栓，3人死亡，美国为什么还要解除强生疫苗禁令？特朗普罕见为疫苗背书
• 【NEJM】解析两名女性接种mRNA疫苗后突破性感染
• Vaccine Breakthrough Infections with SARS-CoV-2 Variants
• Science：疫苗研发不应仅停留在SARS-CoV-2上，通用冠状病毒疫苗箭在弦上
• Covid-19 Vaccines: Misinformation and Hesitancy
• 早产率增加97%！新研究支持孕妇接种新冠疫苗
• Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection The INTERCOVID Multinational Cohort Study
• 医学顶刊BMJ全面解析中国疫苗
• What do we know about China’scovid-19 vaccines?
• Accuracy of rapid antigen detection test for nasopharyngeal swab specimens and saliva samples in comparison with RT-PCR and viral culture for SARS-CoV-2 detection
• Partial immunity and SARS-CoV-2 mutations—Response
• 拯救脓毒症运动关于成人COVID-19的ICU管理指南：第一次更新
• 【在线速递】糖皮质激素对2019新型冠状病毒感染患者预后的影响
• Cell: 王佑春团队最新研究为疫苗优化设计提供重要参考 | Cell Press对话科学家
• SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape
• 打的中国生物疫苗，为何接种信息是兰州生物或成都生物？
• 中国之外，首个灭活疫苗3期试验结果发布；欧洲的类似疫苗快了
• COVID-19疫苗热点简评：血栓疑云、数据披露、灭活疫苗大反转？接种率是王道……
• 科学家发现了两例突破性感染, 某些新冠变异株或可逃避mRNA疫苗
• Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study
• 全球疫苗接种超10亿剂，哪些国家遥遥领先？
• Unprecedented achievement’: who received the first billion COVID vaccinations?
• CDC宣布美国已抵达COVID-19免疫进程的另一个重要里程碑
• 人类的希望！一文读懂mRNA疫苗
• 辉瑞公司mRNA疫苗制造过程首次揭秘
• SARS-CoV-2 variants of concern: the knowns and unknowns
• 我国学者证实，新冠肺炎其实是一种血管疾病，而非呼吸系统疾病
• SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2
• 感染新冠、这位大哥创下新冠最长住院记录
• Nature关注：从备受质疑到成为救世主，中国新冠疫苗迎来高光时刻
• China’s COVID vaccines are going global — but questions remain
• 等待世卫组织批准的中国疫苗或填补全球疫苗缺口
• Nature子刊：我国学者证实新冠病毒能直接感染肾脏，导致急性肾损伤
• Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection
• 炸了！美国宣布放开新冠疫苗专利，疫苗股全线暴跌！对我国影响有多大？
• 美国若放弃新冠疫苗专利，意味着什么？有何影响？
• 新冠病毒是怎么一步步摧毁人体的？最全后遗症曝光
• PLOS Pathogens评述：新冠病毒“反式互补”系统
• Two courses of deconstructed coronavirus please
• “硬刚”美国？德国反对疫苗专利豁免，多家疫苗巨头这样回应！拜登到底为何“慷慨”？
• 《自然》发文: 对许多国家来说, 中国疫苗是唯一可及的疫苗
• 毫无悬念：世卫批准首个中国COVID-19疫苗，美国赶紧放弃疫苗专利
• One dose of SARS-CoV-2 vaccine exponentially increases antibodies in recovered individuals with symptomatic COVID-19
• 对新冠病毒的免疫力能维持多久？
• Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to eight months post-symptom onset
• 福奇Med最新述评：COVID-19的治疗图景
• COVID-19: The therapeutic landscape
• 新冠病毒疫苗宣传海报发布！
• Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis
• Evaluation of potential COVID-19 recurrence in patients with late repeat positive SARS-CoV-2 testing
• Are presymptomatic SARS-CoV-2 infections in nursing home residents unrecognized symptomatic infections? Sequence and metadata from weekly testing in an extensive nursing home outbreak
• 面对印尼公布的数据, 美媒也变了调门: 科兴疫苗现实有效性高于其临床试验结果
• 孙强/黄红艳/刘良团队合作揭示新冠患者淋巴细胞减少症发生的新机制
• SARS-CoV-2 spike protein dictates syncytium-mediated lymphocyte elimination
• 最新研究 | 两剂辉瑞疫苗对预防COVID-19感染、住院和死亡高度有效
• Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
• 中国首款mRNA疫苗开始三期试验
• 疫情防控再添保障，打三针的重组新冠疫苗已于3日下线上市
• 中国首款mRNA疫苗开始三期试验
• 新冠或导致永久性阳痿，2名男子痊愈8个月后仍无法勃起
• New coronavirus lingers in penis and could cause impotence
• Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study
• What incentives can spur Covid-19 vaccination uptake
• 新冠病毒重组疫苗比灭活疫苗更安全有效？河北疾控专家这样说
• 从横尸遍野到世界首个全民免疫之城？中国疫苗逆天改命！
• 哮喘和哮喘药物对COVID-19患者预后的影响
• Effect of asthma and asthma medication on the prognosis of patients with COVID-19
• COVID-19对哮喘患者的影响
• The impact of COVID-19 on patients with asthma
• Specific exposure of ICU staff to SARS-CoV-2 seropositivity: a wide seroprevalence study in a French city-center hospital
• 新冠疫苗两针能打不同款吗？
• 迄今为止最大的研究证实，布洛芬等非甾体抗炎药不会导致COVID-19的结局恶化
• Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study
• 老年人新冠疫苗开打，这3件事要注意！
• 只打一针的新冠疫苗，来了！
• 单针、双针和三针的新冠疫苗有什么区别？打完后哪些能做，哪些不能做？一文说清！
• Evaluation of Cellular and Serological Responses to Acute SARS-CoV-2 Infection Demonstrates the Functional Importance of the Receptor-Binding Domain
• Heterogeneous magnitude of immunological memory to SARS-CoV-2 in recovered individuals
• 不同厂家的新冠疫苗能否混打？一支疫苗给两人接种？权威回应来了
• 再问不回答了，新冠疫苗禁忌症只有两条，其他都可以打
• 美疾控中心前主任：蛋白亚单位疫苗研发平台对于阻止新冠疫情非常重要
• 哪些人不能打新冠疫苗？这42种情况说全了！对照收藏！
• SARS没能逼出来的抗病毒药物能在新冠疫情中研发成功吗？|《自然》特写
• The race for antiviral drugs to beat COVID — and the next pandemic
• Nature | 新冠肺炎组织图谱揭示SARS-CoV-2病理与细胞靶点
• COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets
• 新冠喷雾真的来了？一种可吸入的纳米抗体疗法可防治仓鼠的新冠病毒感染｜Science Advances
• Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses
• 这款被世卫组织认可的新冠疫苗用了什么“黑科技”？
• JAMA重磅：国药发布全球首个新冠灭活疫苗Ⅲ期临床数据
• Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults
• Clinical outcomes in COVID-19 patients infected with different SARS-cov-2 variants in marseille, France
• Nature子刊：哪怕有一个病毒颗粒，我们也漏不掉
• Viruses：新基因测定法助力新冠药物大洗牌
• Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CLpro Inhibitors
• STTT背靠背 | 突破！谭文杰/彭小忠等开发新型的新冠疫苗，在动物试验有效
• A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity
• Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease
• 首次发现：1名癌症患者接种新冠mRNA疫苗后，出现了细胞因子风暴
• Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2
• 病毒学国家重点实验室/中科院武汉病毒所/国家病毒资源库在SARS-CoV-2与血小板和巨核细胞相互作用机制研究中取得新进展
• SARS-CoV-2 interacts with platelets and megakaryocytes via ACE2-independent mechanism
• 科兴疫苗被世卫纳入紧急使用！巴西样本显示75%接种率即可遏制病毒传播，A股市场却闹了个大乌龙？
• 新药物！STING激动剂有效抑制新冠进程！
• Circulating SARS-CoV-2 Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients
• 新冠轻症患者或终身拥有分泌抗体的免疫细胞
• 第一种“失效”的新冠疫苗来了！NEJM：它对南非变异株几无效果……
• Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
• Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
• 新证据：新冠可对儿童器官组织的直接攻击！
• An autopsy study of the spectrum of severe COVID-19 in children: From SARS to different phenotypes of MIS-C
• 为什么接种疫苗时总是选择上臂，而不是其他部位？
• Why do we get shots in the arm? It’s all about the muscle
• Outcome Improvement Between the First Two Waves of the Coronavirus Disease 2019 Pandemic in a Single Tertiary-Care Hospital in Belgium
• 非注射，无痛！陈薇团队：雾化吸入式新冠疫苗已获药监局批准
• 你不知道的故事：我是实验对象NL002-0060，我决定退出新冠候选疫苗试验
• I’m subject NL002-0060 and I’m dropping out of my COVID-19 vaccine trial
• Nature新突破：全新IgM抗体能更有效地对抗新冠病毒
• Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants
• Coagulation factors and the incidence of COVID-19 severity: Mendelian randomization analyses and supporting evidence
• 抗疫再添利器！我国又一新冠病毒灭活疫苗上市使用
• 国产新冠疫苗保护期到底有多长？最新权威回应
• Nature子刊：牛津-阿斯利康腺病毒新冠疫苗与出血性疾病有关
• First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland
• Nature：辉瑞mRNA疫苗可中和变异株，还能保护未接种的人
• BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants
• 变异毒株Delta对接种过疫苗的人仍具有高度传染性
• 2分钟看懂NEJM：单剂Ad26.COV2.S COVID-19疫苗的安全性和效力
• Single-Dose Ad26.COV2.S Vaccine against Covid-19
• 牛津-阿斯利康疫苗与出血性疾病风险轻微升高有关 |《自然-医学》论文
• 中国单日疫苗接种量震惊世界
• China is vaccinating a staggering 20 million people a day
• 辉瑞疫苗可中和新冠病毒新变异 |《自然》论文
• 那些感染新冠的孩子怎么样了？中国科学家揭示新冠病毒与儿童体内微生物菌群关系
• Progressive deterioration of the upper respiratory tract and the gut microbiomes in children during the early infection stages of COVID-19
• High-dimensional characterization of post-acute sequelae of COVID-19
• Out-of-hospital cardiac arrest during the COVID-19 era: The importance to fight against fear
• Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection
• 2021年全球及中国新冠疫苗市场研究报告
• Cell Research详解：新冠病毒印度株等大流行，后面该如何打针做免疫防护？
• Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines
• Science子刊：终于明白为何新冠导致嗅觉丧失
• COVID-19–related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters
• 被严重忽视的新冠感染后长期后遗症，Nature连续发文，提出三个最紧迫的问题
• 新冠病毒"重男轻女"，但其持续症状却可能"重女轻男"
• 广州8个区域将有序解封
• 广州市八医院两名医务人员感染！本土确诊+4！
• Nature：感染新冠后免疫力可维持至少1年
• ​Nature Medicine | 牛津-阿斯利康疫苗与出血性疾病风险轻微升高有关
• 延后第三针接种能产生更强抗体！北大谢晓亮团队揭示不同新冠疫苗对变异株的免疫应答
• 疫苗对预防第二代印度突变株的真实世界保护力发布
• SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness
• Delta变异株已蔓延至74个国家 柳叶刀：感染后的住院风险高出一倍
• COVID-19患者气道上皮病理变化分析
• Analysis of pathological changes in the epithelium in COVID-19 patient airways
• 一图读懂重组新型冠状病毒疫苗（CHO细胞）技术路径
• Cell Res | 陆军军医大学等多单位合作！卞修武/平轶芳/张抒扬​系统揭示了新冠病毒引发的全身发病机制
• A cohort autopsy study defines COVID-19 systemic pathogenesis
• 辉瑞和Moderna疫苗临床保护数据出炉！
• Cancer Cell | 研究证实新冠肺炎疫苗对癌症患者安全有效
• Seroconversion rates following COVID-19 vaccination among patients with cancer
• Update Alert: Remdesivir for Adults With COVID-19
• 斯坦福大学研究发现：COVID-19死亡患者的大脑存在炎症
• 世卫专家：疫苗对“德尔塔”仍有效
• 《柳叶刀》最新研究：两种疫苗对Delta变种病毒有效
• Sci Adv | 袁国勇/陈福和团队发现细胞凋亡通路促进高致病性冠状病毒的毒力
• Targeting highly pathogenic coronavirus-induced apoptosis reduces viral pathogenesis and disease severity
• 重磅：新冠变异株（Delta 变体）全面研究，对中和抗体产生抗性
• SARS-CoV-2 spike P681R mutation enhances andaccelerates viral fusion
• Clinical outcomes in COVID-19 patients infected with different SARS-CoV-2 variants in Marseille, France
• Post-vaccination SARS-CoV-2 infections and incidence of the B.1.427/B.1.429 variant among healthcare personnel at a northern California academic medical center
• 新冠康复后，他们的噩梦才刚刚开始
• 评估轻症患者的“长期新冠”症状 |《自然-医学》
• Long COVID in a prospective cohort of home-isolated patients
• 为什么新冠会多次感染？CELL新研究披露原因
• Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
• A recombinant receptor-binding domain in trimeric form generates protective immunity against SARS-CoV-2 infection in nonhuman primates
• 牛津的试验：混合疫苗、追加疫苗和延长两针间隔时间
• 可预防多种冠状病毒的mRNA疫苗来了；生酮饮食可治心脏病；移植β细胞，治愈糖尿病小鼠丨本周临床快讯
• NEJM|真实世界研究表明mRNA新冠疫苗显著降低无症状感染、病毒载量及症状时间和程度
• Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
• 全球首个！科兴发布3—17岁疫苗研究结果，已获批紧急使用
• Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial
• [科学防治系列科普之一]新冠重组蛋白疫苗好在哪里？
• The Role of Macrolides for the Management of Community-Acquired Pneumonia and Pneumonia by the Novel Coronavirus SARS-CoV-2 (COVID-19): A Position Paper by Four Medical Societies from Greece
• Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2
• COVID-19康复患者的后遗症
• Detailing the Sequelae After Recovery from COVID-19
• 警惕！瑞德西韦治疗新冠肺炎可能会引起严重的心动过缓
• Remdesivir-induced Symptomatic Bradycardia in the treatment of COVID-19 Disease
• 许多新冠肺炎临床研究缺乏生理性别和社会性别多样性 |《自然-通讯》论文
• Lack of consideration of sex and gender in COVID-19 clinical studies
• Large variation in anti-SARS-CoV-2 antibody prevalence among essential workers in Geneva, Switzerland
• 克尔来福疫苗土耳其3期试验中期分析：疫苗安全，可预防疾病
• Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey
• 理解新冠肺炎的遗传风险因素 |《自然》论文
• Mapping the human genetic architecture of COVID-19
• 辉瑞疫苗遭受质疑，对“Delta”变异株的有效率从94%跌至64%！
• NEJM首次发表中国新冠疫苗真实世界研究，智利千万人数据证实灭活疫苗效力
• Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile
• 新论文！新冠康复者可在12个月内持续对抗新冠病毒感染
• Twelve-month specific IgG response to SARS-CoV-2 receptor-bindingdomain among COVID-19 convalescent plasma donors in Wuhan
• Evaluation of a Surrogate ELISA- Based Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) cPass Neutralization Antibody Detection Assay and Correlation with IgG Commercial Serology Assays
• Clinical phenotypes and outcomes of SARS-CoV-2, influenza, RSV and seven other respiratory viruses: a retrospective study using complete hospital data
• 重磅：NEJM发布科兴中维新冠疫苗真实世界研究数据
• STTT综述 | 周玉峰团队论述COVID-19感染的细胞因子风暴信号通路和治疗
• The signal pathways and treatment of cytokine storm in COVID-19
• Cell：无惧病毒变异，T细胞疫苗可对新冠突变株及相关病毒提供广泛保护
• Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses
• COVID患者失去嗅觉是否意味着病毒已经感染了他们的大脑？| Acta Neuropathologica
• The olfactory nerve is not a likely route to brain infection in COVID-19: a critical review of data from humans and animal models
• The SARS-CoV-2 mRNA vaccine breakthrough infection phenotype includes significant symptoms, live virus shedding, and viral genetic diversit
• 国药和科兴成COVAX供应商；国产治疗新冠药物巴西临床；诺诚健华签9.4亿美元license out
• Nature：阿斯利康腺病毒新冠疫苗为何会导致血栓？
• Antibody epitopes in vaccine-induced immune thrombotic thrombocytopenia
• 新冠变种流行之下，需要接种第三针疫苗吗？
• 张林琦/周东明/彭小忠/陈志伟合作研发新型冠状病毒疫苗
• Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection
• 国内首款mRNA疫苗即将获批：复星医药「复必泰」已完成专家审评
• 社论：来势汹汹的德尔塔病毒，现在的疫苗还管用吗？多方数据告诉你，要不要再打一针
• mRNA疫苗作为新冠加强针？NEJM论文有重要提示
• Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination
• 张林琦/张政/王新泉/陈志伟/王佑春合作阐明不同新冠患者体内产生的公共抗体及受病毒突变的影响
• Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2
• 官宣！中国疫苗又传来好消息
• 腺病毒载体疫苗引发血栓原因有新解
• 丰胸针？多名女性称接种疫苗胸部变大，专家：11%的人有类似情况
• STTT | 重大进展！朱凤才团队揭示重组新冠疫苗在 18 岁或以上健康人群中的安全性和免疫原性的结果：安全可靠
• Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials
• Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
• 科研资讯 | 张林琦/周东明/彭小忠/陈志伟合作研发新型冠状病毒疫苗
• Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection
• Science：另辟蹊径！​研究发现细胞抗衰老药物，可降低冠状病毒相关的死亡率
• Senolytics reduce coronavirus-related mortality in old mice
• Targeting aging cells improves survival
• 华人新冠病死率高出其他人种74.3%？对话论文作者
• COVID-19 AND ITS CARDIAC AND NEUROLOGICAL COMPLICATIONS AMONG ONTARIO VISIBLE MINORITIES
• Beyond the new normal: Assessing the feasibility of vaccine-based suppression of SARS-CoV-2
• 抑郁和脑雾：新冠病毒如何损伤大脑？
• COVID and the brain: researchers zero in on how damage occurs
• Nature：即使是mRNA疫苗，也不应跳过第二剂
• Systems vaccinology of the BNT162b2 mRNA vaccine in humans
• 港大：mRNA和灭活病毒疫苗全面比较
• Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19
• Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
• Science | 可减少99%新冠病毒载量！为新冠治疗带来新希望
• Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2
• 肺康复对 COVID-19 患者的益处
• The benefits of pulmonary rehabilitation in patients with COVID-19
• 福音！mRNA与腺病毒载体疫苗有效预防新冠病毒delta变异株
• Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant
• COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants
• SARS-CoV-2 Infections in mRNA Vaccinated Individuals are Biased for Viruses Encoding Spike E484K and Associated with Reduced Infectious Virus Loads that Correlate with Respiratory Antiviral IgG levels
• Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine
• Comparison of COVID-19 vaccine prioritization strategies
• 同时感染2种新冠病毒突变体？最担心的事情发生了！
• Dynamics of a Dual SARS-CoV-2 Lineage Co-Infection on a Prolonged Viral Shedding COVID-19 Case: Insights into Clinical Severity and Disease Duration
• 鼻腔内接种COVID-19疫苗的充分理由｜Science一周精选
• Scent of a vaccine
• The COVID-19 infodemic does not affect vaccine acceptance
• 中山大学等多家单位合作，陆家海/郭城/单鸿/黄曦揭示新冠患者住院期间口腔菌群和肠道菌群的变化
• Altered oral and gutmicrobiota and its association with SARS-CoV-2 viral load in COVID-19 patientsduring hospitalization
• 最新研究 | 近半重症COVID-19住院患者出现一种或多种并发症
• Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study
• Nature子刊：发现青蒿素及其衍生物可抑制SARS-CoV-2病毒感染
• In vitro efficacy of artemisinin-based treatments against SARS-CoV-2
• “人民的希望”：瑞德西韦究竟如何抑制新冠病毒？
• Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
• 以色列研究显示新冠疫苗突破性感染与中和抗体峰值而非滴度下降更相关
• Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
• The SARS-CoV-2 B.1.1.7 variant and increased clinical severity—the jury is out
• Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
• Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients
• 注射新冠疫苗后面瘫——BMJ解释原因
• Sequential contralateral facial nerve palsies following COVID-19 vaccination first and second doses
• SARS-CoV-2抗原检测快速检测与自采集鼻拭子与专业采集鼻咽拭子的比较
• Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swab versus professional-collected nasopharyngeal swab
• The BMJ：新型冠状病毒肺炎：新版指南称，没有证据表明疫苗会影响生育能力【新闻】【2021年第6期】
• Covid-19: No evidence that vaccines can affect fertility, says new guidance
• 研发抗SARS-CoV-2药物没有捷径｜Science一周精选
• No shortcuts to SARS-CoV-2 antivirals
• Impact of SARS-CoV-2 variant-associated RBD mutations on the susceptibility to serum antibodies elicited by COVID-19 infection or vaccination
• Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models
• Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial
• 揭示成年人和儿童对新冠病毒免疫应答的差异 |《自然-通讯》论文
• SARS-CoV-2 specific T cell responses are lower in children and increase with age and time after infection
• Nature子刊：香港大学首次揭示儿童感染新冠后症状较轻的具体原因
• 一朝得新冠，终身有抗体？
• Had COVID? You’ll probably make antibodies for a lifetime
• 最新研究 | 中国首个雾化吸入新冠疫苗研究：安全耐受，可有效激发免疫反应
• NEJM：接种新冠疫苗后哪些患者容易被感染？
• Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
• Cell Res | 神奇！中山大学肖海鹏团队揭示早上接种新冠疫苗，会产生更强的免疫反应
• Time of day influences immune response to an inactivated vaccine against SARS-CoV-2
• Cell Res | 神奇！中山大学肖海鹏团队揭示早上接种新冠疫苗，会产生更强的免疫反应
• Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel
• 2分钟看懂NEJM：托法替布治疗重症COVID-19肺炎
• Tofacitinib for Severe Covid-19 Pneumonia
• 德尔塔变异株流行，“总是有效”的连花清瘟又有效了
• 重要发现！单抗对德尔塔（Delta）等新冠变异株有效
• Screeningof potent neutralizing antibodies against SARS-CoV-2 using convalescentpatients-derived phage-display libraries
• 接连喜报！国药发现对抗德尔塔新药物，康泰生物成功分离出德尔塔变异株，新冠特效药将至？但新变异株也悄悄来了……
• Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2
• Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients
• 德尔塔变异株流行，“总是有效”的连花清瘟又有效了
• 不同COVID-19疫苗混合接种可增强免疫应答
• Heterologous COVID-19 Vaccination Enhances Immune Responses
• Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2
• Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands, February to May 2021
• 以色列抗新冠新药来了！5天内治愈90%重症患者
• NSR | 周溪/尚游/薛宇/黄朝林揭示新冠肺炎致多器官损伤的致病机制
• Postmortem Tissue Proteomics Reveals the Pathogenesis of Multiorgan Injuries of COVID-19
• 最新研究 | COVID-19长期症状在儿童中较少见
• Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2
• Comparability of six different immunoassays measuring SARS-CoV-2 antibodies with neutralising antibody levels in convalescent plasma: from utility to prediction
• Longitudinal evaluation of laboratory-based serological assays for SARS-CoV-2 antibody detection
• 2分钟看懂NEJM：COVID-19疫苗对B.1.617.2（delta）变异株的预防效果
• Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
• Caution When Comparing the Impact of Corticosteroids in COVID-19
• 一支新冠重组蛋白疫苗的诞生
• 新冠疫苗加强针的五问五答 |《自然》长文
• COVID vaccine boosters: the most important questions
• 病毒学国家重点实验室陈宇研究组在冠状病毒减毒活疫苗研究中取得新进展
• Live attenuated coronavirus vaccines deficient in N7-Methyltransferase activity induce both humoral and cellular immune responses in mice
• 武生所已分离出新冠变异德尔塔毒株，正加紧研制疫苗
• 法国研究称Delta发生ADE，吵翻了。。。
• Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination
• Can the cycle threshold (Ct) value of RT-PCR test for SARS CoV2 predict infectivity among close contacts?
• J Hepatol（IF=25）| 兰州大学等多单位合作，祁小龙/张文宏发现非酒精性脂肪性肝病患者接种新冠疫苗安全有效
• Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study
• 肺细胞的年龄依赖性特征与COVID-19的严重程度相关｜Science Advances
• Age-dependent regulation of SARS-CoV-2 cell entry genes and cell death programs correlates with COVID-19 severity
• 张文宏、应天雷点评|SARS幸存者接种新冠疫苗产生抗多种冠状病毒广谱中和抗体
• Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors
• “武汉造”新冠疫苗获批3-17岁人群紧急使用
• Severe COVID-19 by SARS-CoV-2 Lineage B.1.1.7 in Vaccinated Solid-Organ Transplant Recipients: New Preventive Strategies Needed to Protect Immunocompromised Patients
• 鼻细胞差异或致儿童新冠症状较轻 |《自然-生物技术》论文
• Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children
• Sex Differences in Association Between Anti-Hypertensive Medications and Risk of COVID-19 in Middle-Aged and Older Adults
• 重磅：SARS康复者接种新冠疫苗产生超级抵抗力！广谱新冠疫苗指日可待？
• Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized With COVID-19 in the United States: A Retrospective Cohort Study
• A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants
• STTT | 暨南大学吴建国/张其威等发现HIF-1α促进新冠病毒感染并加重对COVID-19的炎症反应
• HIF-1α promotes SARS-CoV-2 infection and aggravates inflammatory responses to COVID-19
• 儿童及青少年需要接种新冠疫苗吗？
• Should children get COVID vaccines? What the science says
• 广东疾控研究：接种两剂国产新冠灭活疫苗对德尔塔毒株有效
• 利用唾液样本可以在一小时内诊断出特定的COVID-19变异｜Science Advances多文导读
• 武汉病毒所周鹏石正丽：无症状感染者可再次感染新冠病毒
• Serological investigation of asymptomatic cases of SARS-CoV-2 infection reveals weak and declining antibody responses
• COVID‐19 and the impact of arterial hypertension—An analysis of the international HOPE COVID‐19 Registry (Italy‐Spain‐Germany)
• PNAS：科学家筛选17种候选药物，发现乳铁蛋白预防新冠功效显著
• Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19
• mRNA疫苗成全球首款正式获批新冠疫苗，国内上市进展如何？
• 潜伏高手：74%的Delta感染发生在症状出现前
• Delta’s rise is fuelled by rampant spread from people who feel fine
• 新冠疫情中一个可怕的敌人——炎症风暴
• 丈夫感染新冠住进ICU，妻子却没事，有人天生对新冠免疫？
• Cross-disciplinary approaches to assist with nucleic acid testing for SARS-CoV-2
• SARS-CoV-2 Vaccines: Where Are We Now?
• 2篇Lancet | 曹彬等团队系统揭示新冠出院患者的情况：恢复良好，后遗症显著减少（值得收藏）
• 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study
• 新冠病毒变种传播力缘何增强 | 谭旭课题组及合作者揭示新冠流行变种具有逃逸人体细胞免疫的普遍特点
• Profiling CD8+ T Cell Epitopes of COVID-19 Convalescents Reveals Reduced Cellular Immune Responses to SARS-CoV-2 Variants
• 智飞生物：Ⅲ期临床试验关键性数据对Delta变异株的保护效力为77.54%
• 揭秘！mRNA疫苗成功上市，是偶然还是必然？
• 为啥胖子这么惨？武汉病毒所张波团队首次建立肥胖相关的新冠疾病感染模型
• Increased morbidity of obese mice infected with mouse-adapted SARS-CoV-2
• 证实！新冠疫苗对Delta的保护力会随时间下降
• COVID vaccines protect against Delta, but their effectiveness wanes
• Experience of Treating COVID-19 With Remdesivir and Convalescent Plasma in a Resource-Limited Setting: A Prospective, Observational Study
• 全方位解读：新冠病毒疫苗加强针！
• Cell Res | 北京大学肖俊宇/谢晓亮/曹云龙揭示使用多种单克隆抗体可针对新冠病毒多种突变株！
• Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants
• 武汉一年后，新冠后遗症还在！《柳叶刀》发布中国学者最新研究
• 《柳叶刀》：新冠康复者大多数1年后仍未完全康复，超六成至少有一种后遗症
• SARS-CoV-2引起脑部病变的机制
• Insights into How SARS-CoV-2 Causes Brain Pathology
• 最新研究 | 与阿尔法变异株相比，德尔塔变异株使COVID-19的住院风险增加一倍
• Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study
• mRNA疫苗真的那么“神”？接种六个月后，还可预防重症和无症状感染
• 为住院和非住院患者多学科会诊中发现的长期 COVID 后遗症描述性分析
• Descriptive analysis of long COVID sequelae identified in a multidisciplinary clinic serving hospitalised and non-hospitalised patients
• 重大突破！全球首款新冠特效药诞生！
• 预印本揭露最新江苏疫情数据！新冠疫苗到底有没有用?!
• Effectiveness of inactive COVID-19 vaccines against severe illness in B.1.617.2 (Delta) variant-infected patients in Jiangsu, China
• Science：先前接触过普通感冒冠状病毒可增强人体对SARS-CoV-2的免疫反应
• Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination
• 印度将推出全球首个新冠DNA疫苗
• India’s DNA COVID vaccine is a world first – more are coming
• 四种新冠疫苗抗体反应直接对比！中国生物疫苗最差？又被黑？
• 打完疫苗还感染，我们应该怎么办？
• 战胜新冠的方法找到了? 新研究: 部分人群已获得“超人般的”混合免疫力
• 王祥喜团队领衔：科兴疫苗加强针数据被揭露！保护效果怎么样？有必要接种吗？
• A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2
• 国产mRNA疫苗龙头渐起，两大核心技术值得关注！
• 别着急打加强针！《柳叶刀》指出过早接种加强针可能存在风险，大多数人无需加强针
• Considerations in boosting COVID-19 vaccine immune responses
• Seasonal coronavirus-specific B-cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19 patients
• Alterations in the Plasma Proteome Induced by SARS-CoV-2 and MERS-CoV Reveal Biomarkers for Disease Outcomes for COVID-19 Patients
• SARS-CoV-2 Vaccines: Where Are We Now?\
• Seroconversion and fever are dose-pependent in a nonhuman primate model of inhalational COVID-19
• Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled Phase 1 Studies in Healthy Subjects and Patients with Mild SARS-CoV-2 Infection
• Single-dose mRNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Including Alpha and Gamma Variants: A Test-negative Design in Adults 70 Years and Older in British Columbia, Canada
• Post-SARS-CoV-2 vaccination specific antibody decrease—Thresholds for determining seroprevalence and seroneutralization differ
• Effectiveness of an Inactivated SARS-CoV-2 Vaccine
• Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce
• Repurposable Drugs for SARS-CoV-2 and Influenza Sepsis with scRNA-Seq Data Targeting Post-Transcription Modifications
• Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination—Kentucky, May–June 2021
• Potential Challenges for Coronavirus (SARS-CoV-2) Vaccines Under Trial
• Characteristics and Outcomes of Over 300,000 Patients with COVID-19 and History of Cancer in the United States and Spain
• 应该给无症状、轻症核酸阳性儿童做CT吗？有医生强烈反对，有医生支持
• Science |大火的mRNA新冠疫苗效果怎样？最新研究发现免疫力至少持续六个月
• Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells
• “吸一吸”的新冠疫苗可能真要来了：安全、有效、可及全面升级
• 国药最新！新冠疫苗3-17岁人群使用数据披露
• Safety andimmunogenicity of an inactivated COVID-19vaccine，BBIBP-CorV, in people younger than 18years: a randomised, double-blind, controlled, phase 1/2 trial
• 儿童不易感染新冠的秘密是什么？|《自然》长文
• Kids and COVID: why young immune systems are still on top
• 评估莫德纳疫苗加强针的安全性和效力 |《自然-医学》论文
• Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
• 谭旭/王林发合作团队从蝙蝠基因组学研究发现广谱抗病毒药物靶点和抗新冠病毒潜在药物分子
• Orthogonal genome-wide screens in bat cells identify MTHFD1 as a target of broad antiviral therapy
• 迄今为止，关于COVID-19疫苗效力的研究证据并不支持普通人群接种疫苗加强针
• Considerations in boosting COVID-19 vaccine immune responses
• 瞿介明教授团队在《Cell Research》发文：揭示区分新冠病毒持续无症状感染者和潜伏期无症状感染者免疫学特征
• 2分钟看懂NEJM：NVX-CoV2373 COVID-19疫苗的安全性和预防效力
• Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
• STTT | 华中科技大学刘超红/卢忠心揭示新冠病毒感染后康复患者的免疫缺陷的潜在机理
• SARS-CoV-2 infection causes immunodeficiency in recovered patients by downregulating CD19 expression in B cells via enhancing B-cell metabolism
• STTT | 华中科技大学刘超红/卢忠心揭示新冠病毒感染后康复患者的免疫缺陷的潜在机理
• Menstrual changes after covid-19 vaccination
• 医学顶刊：呼吁重视新冠疫苗对月经的影响
• Nature子刊：康复后仍免疫缺陷，新冠病毒对B细胞到底还做了什么？！
• SARS-CoV-2 infection causes immunodeficiency in recovered patients by downregulating CD19 expression in B cells via enhancing B-cell metabolism
• Distinct immune signatures discriminate between asymptomatic and presymptomatic SARS-CoV-2subjects
• Cell Research | 瞿介明/诸江/卢洪洲合作阐释区分新型冠状病毒持续无症状感染者和潜伏期无症状感染者免疫学特征
• COVID-19呼吸衰竭的肺支气管动脉吻合
• Intrapulmonary bronchopulmonary anastomoses in COVID-19 respiratory failure
• Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients
• Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
• SARS-CoV-2 seroprevalence among 7,950 health-care workers in the Region of Southern Denmark. (THEIJID-D-21-01420R1)
• Lower antibiotic prescription rates in hospitalized COVID-19 patients than influenza patients, a prospective study
• A single dose of the Biontech/Pfizer BNT162b2 vaccine protected elderly residents from severe COVID-19 during a SARS-coronavirus-2 outbreak in a senior citizen home in Germany
• Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial
• Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients
• Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
• Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab
• Clinical outcomes in COVID-19 patients infected with different SARS-CoV-2 variants in Marseille, France
• Performance of a Surrogate SARS-CoV-2-Neutralizing Antibody Assay in Natural Infection and Vaccination Samples
• 不甘人后，中国团队研发口服抗新冠病毒药物
• Design and development of an oral remdesivirderivative VV116 against SARS-CoV-2
• 新型单克隆抗体为冠状病毒感染的预防和治疗带来希望
• New Monoclonal Antibodies Offer Hope for Preventing and Treating Coronavirus Infections
• 默沙东新冠口服药成功，疫苗和中和抗体概念股纷纷大跌
• 要打三针的新冠疫苗是什么？是怎么诞生的？
• 【药化】靶向新型冠状病毒S1蛋白的中和多肽阻遏病毒感染宿主细胞
• Synthetic Neutralizing Peptides Inhibit the Host Cell Binding of Spike Protein and Block Infection of SARS-CoV-2
• 新冠疫苗为何无缘今年的诺贝尔奖？
• Why COVID vaccines didn’t win a science Nobel this year
• 最新研究 | 两剂BNT162b2疫苗预防新冠住院的高度有效性可至少维持六个月
• Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
• 2分钟看懂NEJM：SARS-CoV-1感染康复者接种COVID-19疫苗后的防护作用
• Protective Effects of Covid-19 Vaccines in SARS-CoV-1 Survivors
• 新冠病毒终结者？Merck的新冠药物到底有多大用？
• 疾控中心病毒病所刘军、高福、武桂珍：新冠康复者在感染后1年仍具有T细胞和抗体免疫记忆
• One-year sustained cellular and humoral immunities of COVID-19 convalescents
• COVID-19 Vaccines: Immune Response after Vaccination against SARS-CoV-2 Infections
• Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial
• Weak Cross-Lineage Neutralization by Anti SARS-CoV-2 Spike Antibodies after Natural Infection or Vaccination Is Rescued by Repeated Immunological Stimulation
• Effect of Vaccination on Transmission of SARS-CoV-2
• Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in a Subgroup of Healthy Adults in Chile
• Clinical outcomes in patients infected with different SARS-CoV-2 variants at one hospital during three phases of the COVID-19 epidemic in Marseille, France
• 深度好文|国内新冠口服药VV116到底是啥？和瑞德西韦、默沙东口服药有何区别
• 长期新冠肺炎表型
• Phenotyping long COVID
• 用于 COVID-19 患者风险分层和治疗指导的肺部超声评估：一项前瞻非干预性研究
• Point-of-care lung ultrasound assessment for risk stratification and therapy guiding in COVID-19 patients: a prospective noninterventional study
• 科学家开发新的SARSCov2抗体检测技术，使用手机5分钟内即可完成｜Science Advances多文导读
• Nature:中国疫苗到了接种第三针的时候了
• 新冠口服药井喷！郭德银、张绪穆合作开发的口服抗新冠候选药物
• 荷兰专家答记者问：面对数字上升为什么现在还不采取措施？
• 罗氏新冠药物临床不如预期！口服药路漫漫
• 一图读懂-什么是mRNA疫苗？
• “吹口气测新冠”成为可能！中国科学家研发出快速筛查技术
• Nature Immunology | 曹雪涛应邀撰写新冠病毒感染易发炎症反应的评论
• ISG15 secretion exacerbates inflammation in SARS-CoV-2 infection
• 超级免疫：新冠疫情最大的谜题之一
• COVID super-immunity: one of the pandemic’s great puzzles
• COVID-19对肺功能、相关容量和生活质量的中期影响
• Medium-term impact of COVID-19 on pulmonary function, functional capacity and quality of life
• 辉瑞：接种mRNA新冠疫苗加强针后有效率为95.6％
• COVID-19康复者的SARS-CoV-2再次感染风险
• Elucidating Reinfection After COVID-19
• Trends, patterns and psychological influences on COVID-19 vaccination intention: findings from a large prospective community cohort study in England and Wales (Virus Watch)
• Monetary incentives increase COVID-19 vaccinations
• Psychosocial Determinants of COVID-19 Vaccination Intention Among White, Black, and Hispanic Adults in the US
• Human nasal wash RNA-seq reveals distinct cell-specific innate immune responses between influenza and SARS-CoV-2
• Comparing Five SARS-CoV-2 Antibody Assay Results Before and After the First and Second ChAdOx1 nCoV-19 Vaccination Among Health Care Workers: A Prospective Multicenter Study
• Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial
• Validation of the effectiveness of SARS-CoV-2 vaccines in older adults in "real-world" settings
• The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study
• Assessing influenza vaccination success to inform COVID‐19 vaccination campaign
• Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern
• Prior infection and age impacts antibody persistence after SARS-CoV-2 mRNA vaccine
• Effect of Inactivated Influenza Vaccination on Human Coronavirus Infection: Secondary Analysis of a Randomized Trial in Hutterite Colonies
• Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
• Attitudes toward the SARS-CoV-2 and Influenza Vaccination in the Metropolitan Cities of Bologna and Palermo, Italy
• Clusters of SARS-CoV-2 Lineage B. 1.1. 7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines
• Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: A double-blind, randomized controlled phase 1/2 trial
• 重医校长黄爱龙领衔：“抵抗多种突变株的新冠病毒超强中和抗体”最新重要发现
• PotentSARS-CoV-2 neutralizing antibodies with protective efficacy against newlyemerged mutational variants
• A Rapid and EfficientScreening System for Neutralizing Antibodies and Its Application forSARS-CoV-2
• 复旦大学应天雷/宋元林/杨振霖团队报道靶向新冠病毒新型表位的全人源单域中和抗体
• A non-ACE2 competing human single-domain antibodyconfers broad neutralization against SARS-CoV-2 and circulating variants
• 84%新冠患者出现后遗症，真相太残酷，但不得不说！
• 黄爱龙教授新成果：“新型冠状病毒感染诱导机体特异性体液免疫反应的新认识”
• Realization of humoral immunity against SARS-CoV-2 infections
• 疫苗有效性降低，是Delta惹得祸吗？
• 特效药来了:辉瑞新冠口服药降低住院或死亡率89%,市值大涨250亿美元
• 最新研究 | 用氟伏沙明治疗新冠或可降低长期住院的风险
• Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial
• 默沙东大屏秀新冠口服药，复星晒mRNA疫苗包装盒
• 2分钟看懂NEJM：BNT162b2 COVID-19疫苗在6个月随访期间的结果
• BNT162b2 Covid-19 Vaccine over 6 Months of Follow-up
• Science：新冠疫苗的有效性正在快速下降
• SARS-CoV-2 vaccine protection and deaths among US veterans during 2021
• 取消防疫措施，只靠疫苗行不行？
• Why scientists worldwide are watching UK COVID infections
• Neutralizing Antibody Response to Pseudotype SARS-CoV-2 Differs between mRNA-1273 and BNT162b2 COVID-19 Vaccines and by History of SARS-CoV-2 Infection
• Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021
• Effectiveness of ChAdOx1 vaccine in older adults during SARS-CoV-2 Gamma variant circulation in São Paulo
• Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates
• Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine
• Germinal center-induced immunity is correlated with protection against SARS-CoV-2 reinfection but not lung damage
• Symptom monitoring after coronavirus disease 2019 (COVID-19) vaccination in a large integrated healthcare system: Separating symptoms from severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection
• Monetary incentives increase COVID-19 vaccinations
• COVID-19 Vaccine Misinformation and Disinformation Costs an Estimated $50 to $300 Million Each Day
• Characteristics and Outcomes of US Patients Hospitalized With COVID-19
• Factors associated with COVID-19 Vaccine Hesitancy in Thai Seniors
• Scientific Reports：50岁以上人群感染新冠后的抗体水平更高
• Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins
• 军事科学院秦成峰教授谈国产新冠病毒mRNA疫苗
• 问题疫苗致22万人感染病毒，研制者“去死的心都有”
• 深圳三院第一手数据：接种第三针灭活疫苗到底有没有用
• 新冠mRNA疫苗进入人体后，是如何发挥作用的？
• 多款新冠口服药获进展，但是科学家有这几点担忧
• 新冠疫苗加强针接种问答
• 一针管一个月！中国自主研发新冠特效药能防变异株
• 新冠特效药能改变疫情走向吗？
• COVID antiviral pills: what scientists still want to know
• 新冠疫苗加强针怎么选？混合接种还是“从一而终”？
• 寻找新冠病毒“天然免疫者”
• 老药新用治疗新冠疾病？网络医学框架加速药物研发
• 抗新冠病毒感染的能力提示新的疫苗靶点 |《自然》论文
• Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2
• 儿童打新冠疫苗对全球疫情有何意义？
• What COVID vaccines for young kids could mean for the pandemic
• Potential global impacts of alternative dosing regimen and rollout options for the ChAdOx1 nCoV-19 vaccine
• Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern
• SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers
• Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: A double-blind, randomized controlled phase 1/2 trial
• Severity of Disease Among Adults Hospitalized with Laboratory-Confirmed COVID-19 Before and During the Period of SARS-CoV-2 B.1.617.2 (Delta) Predominance — COVID-NET, 14 States, January–August 2021
• Seroprevalence of anti-SARS-CoV-2 IgG at the first epidemic peak in French Guiana, July 2020
• Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year
• SARS-CoV-2 seroprevalence in children and their family members, July–October 2020, Brussels
• BNT162b2 vaccine effectiveness was marginally affected by the SARS-CoV-2 beta variant in fully vaccinated individuals
• Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore
• Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves
• 微生物所严景华团队在新冠疫苗诱导抗体库的比较研究中取得新进展
• Nature | 仅非编码区改造的mRNA疫苗诱导与辉瑞疫苗类似的强效免疫
• 2分钟看懂NEJM：SARS-CoV-2中和抗体sotrovimab治疗早期COVID-19
• SARS-CoV-2中和抗体sotrovimab早期治疗COVID-19
• 中国多个国产新冠药物已完成或进入临床试验
• 1到100万 中国新冠药物从论文“落地”成订单
• 降低 COVID-19 感染风险 83%：阿斯利康长效新冠中和抗体两项 III 期临床取得积极结果
• NEJM | 迎来好消息！索托维单抗可显著降低新冠肺炎高风险人群病情进展风险
• Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
• Cell Res | 重大进展！复旦大学张文宏团队发现第三针新冠异源蛋白亚单位疫苗接种，是安全有效的
• Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern
• 比mRNA疫苗更具优势的新冠蛋白质疫苗来了
• How protein-based COVID vaccines could change the pandemic
• 第三剂BNT162b2 mRNA疫苗可有效预防COVID-19严重结局影响
• Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
• Cell Res：张文宏团队最新研究证实，新冠疫苗加强针效果显著！
• Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern
• 新型新冠疫苗I期试验结果乐观 |《自然》论文
• A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity
• 再次感染新冠病毒后病情严重吗？NEJM大数据回答
• Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections
• 接种新冠病毒疫苗加强针后，多久能献血？
• 零死亡！中国新冠特效药“候选种子”三期临床揭盲
• 中国团队新冠后遗症研究：出院近一年，仍会呼吸急促、抑郁
• 短讯|四家疫苗研发厂家在第一时间启动了针对新型变异体奥米克疫苗实验室测试
• 武汉协和医院新研究：新冠肺炎患者出院近1年，仍会呼吸急促、抑郁…
• MSD的抗新冠药物疗效低于预期等 — 11月27日
• 知情人透露：荷兰疫情危机应对小组OMT内部分歧很大
• 从南非返回荷兰61人证实感染必须隔离，还有5千人要检测
• 荷兰政府11月26日晚上宣布的疫情防控新措施有哪些？
• 防示威荷警封锁市中心出入口等 — 11月28日
• 欧洲疫情点滴：瑞士多数人支持健康通行证等
• 坚持留在南非的三名荷兰高尔夫运动员谈现状
• 更多感染变种病毒奥密克戎个案出现，引起对疫苗作用的担忧
• 荷兰证实从南非返回旅客中13人感染奥密克戎，新的变体祸兮福兮？
• Regional Differences in COVID-19 Vaccine Hesitancy in December 2020: A Natural Experiment in the French Working-Age Population
• Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2
• Symptom monitoring after coronavirus disease 2019 (COVID-19) vaccination in a large integrated healthcare system: Separating symptoms from severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection
• Clinical Phenotype and Contagiousness of Early Breakthrough SARS-CoV-2 Infections after BNT162b2 COVID-19 mRNA Vaccine: A Parallel Cohort Study in Healthcare Workers
• Widely heterogeneous humoral and cellular immunity after mild SARS-CoV-2 infection in a homogeneous population of healthy young men
• 在重症监护环境外接受持续气道正压通气/高流量鼻氧治疗的 COVID-19 患者的结果和特征
• Outcomes and characteristics of COVID-19 patients treated with continuous positive airway pressure/high-flow nasal oxygen outside the intensive care setting
• 阿尔茨海默病和新冠感染存在相同的遗传风险因子 | Brain
• Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses
• Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study
• 中国正快速推进奥密克戎株疫苗研发
• Cell：新冠病毒造成嗅觉失灵的原因竟是感染嗅觉上皮的支柱细胞！
• Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb
• 新论文揭示Omicron毒株会突破免疫屏障，全球第二轮疫苗研发竞赛加速打响
• Cell Res | 重大进展！张文宏及谢晓亮等团队发现新冠疫苗加强针安全有效，免疫反应异源接种疫苗强于同源接种疫苗
• Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern
• Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola
• Clinical and virological impact of single and dual infections with influenza A (H1N1) and SARS-CoV-2 in adult inpatients
• Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial
• A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection
• Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins
• 首个国产新冠特效药获批：对变异株效果如何？还有哪些在研？
• 范雄林/陶生策/汪峰等合作探索预测新冠肺炎临床结局的生物标志物
• Anti-SARS-CoV-2 IgG responses are powerful predicting signatures for the outcome of COVID-19 patients
• 最新研究 | 六种不同COVID-19加强针都是安全的，但免疫反应差异较大
• Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
• 最新研究 | 应考虑优先为哮喘控制不佳的5-17岁人群接种新冠疫苗
• Risk of COVID-19 hospital admission among children aged 5–17 years with asthma in Scotland: a national incident cohort study
• 恐怖的新冠：研究发现，重症幸存者面临12月内死亡高风险
• COVID-19 Post-acute Sequelae Among Adults: 12 Month Mortality Risk
• Severe COVID Increases Mortality Risk in Following Year: Study
• 智飞生物:重组新冠疫苗(CHO 细胞)对奥密克戎变异株依然有效
• 疫苗混合接种后T细胞反应结果令人惊讶 蛋白疫苗表现突出
• 或将面临巨额索赔，Moderna新冠疫苗关键专利败诉
• 余宏杰课题组在新冠灭活疫苗的免疫持久性 及加强免疫研究领域取得重要进展
• Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials
• 老年危重 COVID-19 患者的类固醇使用
• Steroid use in elderly critically ill COVID-19 patients
• 吸入性泛 JAK 抑制剂奈珠西替尼 (TD-0903) 治疗重症 COVID-19 的 2 期多剂量递增研究
• A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19
• Lancet子刊/Cell Res | 重大进展！余宏杰，张文宏及谢晓亮等团队发现新冠疫苗加强针安全有效
• 中国首个抗新冠病毒特效药获批上市！Front. Microbiol. 栏目主编张林琦教授领衔研发！
• Vaccination as an Alternative to Non-Drug Interventions to Prevent Local Resurgence of COVID-19
• Humoral Immune Response following SARS-CoV-2 Vaccination in Liver Transplant Recipients
• Humoral anti-SARS-CoV-2 immune response after two doses of Comirnaty vaccine in nursing home residents by previous infection status
• Assessment of SARS-CoV-2 Seroprevalence by Community Survey and Residual Specimens, Denver, Colorado, July–August 2020
• WHO international standard for SARS-CoV-2 antibodies to determine markers of protection
• Antibody response to SARS-CoV-2 for more than one year− kinetics and persistence of detection are predominantly determined by avidity progression and test design
• Efficacy and Safety of the CVnCoV SARS-CoV-2 mRNA Vaccine Candidate: Results from Herald, a Phase 2b/3, Randomised, Observer-Blinded, Placebo-Controlled Clinical Trial in Ten Countries in Europe and Latin America
• Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection
• 港大分离Omicron病毒株 已送中国疾控中心、科兴及国药
• 奥密克戎席卷南非，因疫苗不够？其实仓库里的疫苗都快过期了……
• COVID-19新药molnupiravir失去了光环
• COVIR-赵金存团队受邀发表人冠状病毒诱导免疫应答综述
• Immune responses to human respiratory coronaviruses infection in mouse models
• 明查｜莫德纳新冠疫苗2018/19年就获批专利？
• 这种能“捕获”新冠病毒的口香糖，真的能降低传染风险吗？
• Debulking SARS-CoV-2 in saliva using angiotensin converting enzyme 2 in chewing gum to decrease oral virus transmission and infection
• 一家医院，如何参与研制出中国首个新冠抗体药？
• 中国首篇经国际同行评议的疫苗加强接种对抗奥密克戎的数据公布：命运还掌握在人类手中
• 美媒：美国陆军研发出能抗所有变种病毒的超级疫苗
• A Single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern
• Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial
• Antibody cocktail effective against variants of SARS-CoV-2
• A Higher Antibody Response Is Generated With a 6- to 7-Week (vs Standard) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Dosing Interval
• Performance Evaluation of the BZ COVID-19 Neutralizing Antibody Test for the Culture-Free and Rapid Detection of SARS-CoV-2 Neutralizing Antibodies
• COVID-19疫苗的突破和加强剂｜Science一周精选
• COVID-19 vaccine breakthrough infections
• FDA批准首个新冠口服药，可降低88%住院或死亡风险
• 柳叶刀 | 3期试验显示单剂量Ad5-nCoV疫苗安全有效，对重症新冠的保护效力为91.7%
• Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial
• 张文宏最新研究：第三针加强针提供对奥密克戎毒株的保护作用
• Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost
• Science| Omicron变异对新冠疫苗的接种改变
• Sequential infections with rhinovirus and influenza modulate the replicative capacity of SARS-CoV-2 in the upper respiratory tract
• Managing waning vaccine protection against SARS-CoV-2 variants
• 全球首个！二代新冠疫苗获批紧急使用
• A Phase 2a clinical trial of Molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus
• Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant
• Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection
• 评估奥密克戎对抗体和疫苗的抗性 |《自然》论文
• 新冠特效药要来了！治新冠就像治感冒？
• 徐建青/张晓燕等研发了一款能同时抗新型冠状病毒及甲型流感病毒的超广谱疫苗
• A single vaccine protects against SARS-CoV-2 and influenza virus in mice
• 尸检报告：新冠病毒漫步全身，包括大脑
• 广州健康院王建华/郑永唐/陈新文等合作揭示新冠病毒诱导肺炎症损伤的新机制并提出抗炎新策略
• SARS-CoV-2-triggered mast cell rapid degranulation induces alveolar epithelial inflammation and lung injury
• SARS-CoV-2 infection and persistence throughout the human body and brain
• 赠书福利丨后疫情时代，你真的了解疫苗吗？
• Clin Gastro Hepatol | 连续取得进展！张文宏/祁小龙发现慢性肝病人群接种新冠疫苗是安全的
• Safety and immunogenicity of SARS-CoV-2 vaccines in patients with chronic liver diseases (CHESS-NMCID 2101): A multicenter study
• Cell重磅！两篇研究表明接种第三针疫苗对奥密克戎变异株有积极作用 | Cell Press论文速递
• The Omicron variant is highly resistant against antibody-mediated neutralization – implications for control of the COVID-19 pandemic
• mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
• 中国的新冠病毒特效药来了，这对我们意味着什么？
• 口服植物乳杆菌可增强新冠疫苗的免疫效果｜徐建国院士和徐建青教授团队Frontiers in Nutrition
• Boosting Vaccine-Elicited Respiratory Mucosal and Systemic COVID-19 Immunity in Mice With the Oral Lactobacillus plantarum
• 最新数据：中国生物重组蛋白新冠疫苗序贯接种获得更高免疫效力
• Nature揭示新冠康复者及疫苗接种后人群的血清抗体对omicron株的中和活性
• Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
• A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern
• Comparison of the Development of SARS-Coronavirus-2-Specific Cellular Immunity, and Central Memory CD4+ T-Cell Responses Following Infection versus Vaccination
• Heterologous prime-boost immunizations with chimpanzee adenoviral vectors elicit potent and protective immunity against SARS-CoV-2 infection
• Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant
• Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans
• Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI)
• Increased transmissibility of SARS-CoV-2 lineage B. 1.1. 7 by age and viral load
• Randomized controlled trial transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infection
• PCR performance in the SARS-CoV-2 Omicron variant of concern?
• Effect of Previous SARS-CoV-2 Infection on Antibody Response to a Single Immunization with the Pfizer BNT162b mRNA Vaccine Among Healthcare Workers in Foggia, Italy
• A study on the demographic, clinical, and radiological profile of lineage B.1.1.7 (United Kingdom) strain Covid-19 patients at Telangana institute of medical sciences and research, Hyderabad
• Comparative Evaluation of Immune Responses and Protection of Chitosan Nanoparticles and Oil-Emulsion Adjuvants in Avian Coronavirus Inactivated Vaccines in Chickens
• Early signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with COVID-19 caused by the Omicron variant of SARS-CoV-2 in Houston, Texas
• Magnitude and breadth of neutralizing antibody responses elicited by SARS-CoV-2 infection or vaccination
• A Pre-Vaccination Baseline of SARS-CoV-2 Genetic Surveillance and Diversity in the United States
• Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers
• A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2
• mRNA-1273 vaccine-induced antibodies maintain Fc-effector functions across SARS-CoV-2 Variants of Concern
• SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses
• Omicron不易损伤肺部，或比Delta更温和
• Omicron’s feeble attack on the lungs could make it less dangerous
• 我国科学家发现治疗新冠新策略：使用微粒与病毒结合
• 新冠疫苗对苏格兰孕妇的保护作用 |《自然-医学》论文
• SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland
• STTT | 郑爱华课题组研发新型冠状病毒的鼻喷疫苗
• Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein
• 最新研究：新冠感染导致男性生殖器缩小，勃起功能障碍！
• 以不變應萬變—姜肽公呼吁研发β属冠状病毒通用疫苗防控现在的新冠变异株和未来的SARS-CoV-3或MERS-CoV-2
• 前沿速递 | 江苏省农科院兽医所李彬团队在冠状病毒药物研究领域取得重要进展
• JIB-04 Has Broad-Spectrum Antiviral Activity and Inhibits SARS-CoV-2 Replication and Coronavirus Pathogenesis
• Thorax | 吸烟极有可能加重新冠肺炎病情，增加死亡风险
• Smoking and COVID-19 outcomes: an observational and Mendelian randomisation study using the UK Biobank cohort
• 识别与新冠肺炎有关的嗅觉或味觉丧失的遗传风险因素 |《自然-遗传学》论文
• The UGT2A1/UGT2A2 locus is associated with COVID-19-related loss of smell or taste
• Cell Research|姜世勃/陆路/赵金存等在新型佐剂的β属冠状病毒B谱系候选通用疫苗获得突破
• A novel STING Agonist-Adjuvanted Pan-Sarbecovirus Vaccine Elicits Potent and Durable Neutralizing Antibody and T Cell Responses in Mice, Rabbits and NHPs
• 母婴传播新冠病毒或极为罕见 |《自然-通讯》论文
• Maternal-fetal immune responses in pregnant women infected with SARS-CoV-2
• Nature子刊|胎盘能保护胎儿不受感染
• COVID-19的神经系统后果｜Science一周精选
• Nervous system consequences of COVID-19
• 哈兽研团队在ISG抗新冠病毒取得重大突破
• Alpha-Soluble NSF Attachment Protein Prevents the Cleavage of the SARS-CoV-2 Spike Protein by Functioning as an Interferon-Upregulated Furin Inhibitor
• 她患上新冠后只能截肢保命，这类病例正变得越来越多
• Some COVID Patients Need Amputations to Survive
• Advanced Science | 冷泠/王曼丽/周亦武/张抒扬首次揭示新冠患者脱发后遗症的原因
• 新冠疫苗影响生娃？研究结果来了
• 新冠一代：疫情会如何影响儿童的大脑发育？｜《自然》长文
• The COVID generation: how is the pandemic affecting kids’ brains?
• COVID-19 前后的间质性肺病：双重威胁？
• Interstitial lung disease before and after COVID-19: a double threat?
• 中科院动物所郑爱华课题组VSV载体新冠鼻喷疫苗新进展
• 南非SARS-CoV-2奥密克戎变异株临床严重程度的早期评估
• Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study
• 蓝柯/严欢/陈宇/蔡昆团队揭示新冠疫情早期康复者血清对奥密克戎突变株的中和能力大幅下降
• Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents
• Advanced Science | 新冠患者脱发后遗症的原因首次被揭示
• Establishment of Human Pluripotent Stem Cell-Derived Skin Organoids Enabled Pathophysiological Model of SARS-CoV-2 Infection
• NEJM发表中国研究：灭活疫苗中和omicron变异株的能力
• Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant
• 新冠病毒对男性的打击更大？事实果真如此吗？
• Nature重磅 | 王祥喜/秦川/王佑春/秦成峰首次发现打了新冠加强针的人更能抵抗奥密克戎
• Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants
• Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron
• Cell +Nature| 王祥喜团队等报道新冠灭活疫苗加强针可实现对奥密克戎突变株感染的重症保护
• Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron
• Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants
• Nat Med | 朱凤才/陈薇合作团队发表我国首个新冠疫苗序贯免疫的随机对照临床研究——灭活疫苗+Ad5腺病毒载体疫苗
• Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
• Addressing the root of vaccine hesitancy during the COVID-19 pandemic
• Clinical outcomes among patients infected with Omicron (B. 1.1. 529) SARS-CoV-2 variant in southern California
• Assessing the clinical severity of the Omicron variant in the Western Cape Province, South Africa, using the diagnostic PCR proxy marker of RdRp target delay to distinguish between Omicron and Delta infections – a survival analysis
• Sero-Prevalence of Covid-19 among workers in Malaysia
• Severe outcomes in residents of Long Term Care Facilities following infection with SARS-CoV-2 Omicron variant (VIVALDI study)
• Incidence of positive SARS-CoV-2 PCR after COVID-19 vaccination with up to eight months of follow-up: Real life data from the Capital Region of Denmark
• Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil
• Randomized controlled trial transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infection
• Vaccines Elicit Highly Cross-Reactive Cellular Immunity to the SARS-CoV-2 Omicron Variant
• A binding-enhanced but enzymatic activity-eliminated human ACE2 efficiently neutralizes SARS-CoV-2 variants
• Increased small particle aerosol transmission of B.1.1.7 compared with SARS-CoV-2 lineage A in vivo
• Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost
• A Single Vaccine Protects against SARS-CoV-2 and Influenza Virus in Mice
• Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination
• Sequential infections with rhinovirus and influenza modulate the replicative capacity of SARS-CoV-2 in the upper respiratory tract
• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody lateral flow assay for antibody prevalence studies following vaccination: a diagnostic accuracy study
• SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against SARS-CoV-2 Delta and Omicron that can be predicted by anti-S antibody concentrations in serological assays
• Neutralizing antibodies against the SARS-CoV-2 Omicron variant following homologous and heterologous CoronaVac or BNT162b2 vaccination
• Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
• Rapid and Accurate Identification of SARS-CoV-2 Omicron Variants Using Droplet Digital PCR (RT-ddPCR)
• Langerhans cells and cDC1s play redundant roles in mRNA-LNP induced protective anti-influenza and anti-SARS-CoV-2 responses
• Impact of previous SARS-CoV-2 infection on the rate of mortality in dengue. A preliminary report from Pakistan
• NEJM | 迎来好消息！高福团队首次发现适当延长加强针的接种间隔，更能抵抗奥密克戎
• Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant
• 中科院微生物所联合多家机构全面评价国产新冠疫苗对奥密克戎有效性！
• Impact of various vaccine boosters on neutralization against Omicron following prime vaccinations with inactivated or adenovirus-vectored vaccine
• 特定抗体对奥密克戎的有效性 |《自然》论文
• Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants
• 迎来好消息！4连发，陈薇/谢晓亮/张文宏/余宏杰等团队表明新冠疫苗加强针安全有效，免疫反应异源接种疫苗强于同源接种疫苗
• Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
• 世界首例故意感染COVID-19志愿者的研究取得初步成果
• 最新报道新冠灭活疫苗加强针可通过提升B细胞免疫记忆实现对奥密克戎突变株感染的保护
• 三针、四针或更多，我们还需要打多少加强针？
• Nat Microbiol | 南方科技大学刘映霞/袁静发现有症状的新冠感染的康复者中和抗体反应持续时间可长达480天
• Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection
• Durability of Anti-Spike Antibodies in Infants After Maternal COVID-19 Vaccination or Natural Infection
• 新冠病毒让男性生殖器变小？事实果真如此吗？
• 大跌眼镜：Moderna针对Omicron特异性疫苗竟不如初始疫苗！
• Indirect protection of children from SARS-CoV-2 infection through parental vaccination
• IgG Against Human β-Coronavirus Spike Proteins Correlates with SARS-CoV-2 anti-Spike IgG Responses and COVID-19 Disease Severity
• Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses
• Anti-SARS-CoV-2 spike protein and neutralizing antibodies at 1 and 3 months after three doses of SARS-CoV-2 vaccine in a large cohort of solid organ transplant patients
• Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
• 中国应急批准辉瑞新冠口服药：适应证，禁忌证，临床试验
• 刚刚！首款进口新冠口服药获批 可降低89%住院死亡风险
• 《Cell》提醒！接种疫苗比自然感染的免疫效果更好
• Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination
• Lancet Voice | 新冠疫苗接种率及伦敦奥密克戎感染情况
• STTT | 终于解开谜底！夏宁邵/程通/管轶发现女性感染新冠病毒症状更轻的原因：性激素黄体酮起重要作用
• Female sex hormone, progesterone, ameliorates the severity of SARS-CoV-2-caused pneumonia in the Syrian hamster model
• Cell Research重磅：秦成峰团队发布全球首个Omicron特异性mRNA疫苗动物实验数据
• 最新研究 | SARS-CoV-2 mRNA疫苗ARCoV 在中国成人中的安全性和免疫原性研究
• Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial
• 保护仓鼠不受新冠病毒感染的抗病毒药物 |《自然-通讯》论文
• The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV2 variants of concern
• Omicron解剖结构曝光：找到“飞速传播”的原因了！
• Omicron’s Surprising Anatomy Explains Why It Is Wildly Contagious
• 升级版 Omicron传入深圳，入侵40多国，核酸也难检测出！新冠后遗症已增至200种，很多症状恐伴随终身！
• COVID-19 will continue but the end of the pandemic is near
• FMD｜儿童表现出疑似新冠症状时，医生该如何处理？
• Clinical manifestations and pathogen characteristics in children admitted for suspected COVID-19
• Science子刊：从新冠康复者提取超级抗体，可抗多种冠状病毒
• A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection
• 香港大学袁国勇团队证实新冠病毒会导致睾丸损伤和萎缩，康复患者应关注性腺机能减退和生育率降低问题
• [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections by intranasal or testicular inoculation induces testicular damage preventable by vaccination in golden Syrian hamsters](https: //doi.org/10.1093/cid/ciac142)
• 不同疫苗接种策略对新冠肺炎变种病毒的免疫原性比较 | MDPI Vaccines
• Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants
• Cell：新开发的吸入式疫苗可对SARS-CoV-2变体提供广泛保护
• Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2
• Cell Research：我国科学家开发“长效型”新冠病毒mRNA抗体
• Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters
• SARS-CoV-2 Omicron variant virus isolates are highly sensitive to interferon treatment
• Low rate of transmission to triple-vaccinated contacts of an imported case of SARS-CoV-2 omicron infection: A contact tracing study in Israel
• Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants
• Rapid detection and characterization of SARS-CoV-2 omicron variant in a returning traveler
• SARS-CoV-2 Cross-Reactivity in Prepandemic Serum from Rural Malaria-Infected Persons, Cambodia
• SARS-CoV-2 Vaccination boosts Neutralizing Activity against Seasonal Human Coronaviruses
• A non-ACE2-blocking neutralizing antibody against Omicron-included SARS-CoV-2 variants
• Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model